var title_f18_41_19088="Contents: Pediatric nephrology";
var content_f18_41_19088=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric nephrology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric nephrology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute renal failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27114\">",
"           Acute kidney injury (acute renal failure) in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/53/19290\">",
"           Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8472\">",
"           Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/7/23673\">",
"           Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/16/42249\">",
"           Prevention and management of acute kidney injury (acute renal failure) in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic kidney disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28042\">",
"           Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11418\">",
"           Clinical presentation and evaluation of chronic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/18/26919\">",
"           Epidemiology, etiology, and course of chronic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/14/27881\">",
"           Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/17/32026\">",
"           Overview of the management of chronic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/24/37258\">",
"           Uremic toxins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic Renal Failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/31/28153\">",
"           Chronic peritoneal dialysis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/1/9242\">",
"           Hemodialysis for children with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/30/12774\">",
"           Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/54/36713\">",
"           Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17240\">",
"           Prevention and management of growth failure in children with chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital and genetic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/59/33721\">",
"           Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28584\">",
"           Autosomal dominant polycystic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/13/29913\">",
"           Autosomal recessive polycystic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/33/36377\">",
"           Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/22/16744\">",
"           Clinical manifestations, diagnosis, and treatment of nephronophthisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7753\">",
"           Congenital and infantile nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/18/12584\">",
"           Cystinosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/30/32231\">",
"           Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/56/10120\">",
"           Genetics and pathogenesis of nephronophthisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24663\">",
"           Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/59/1973\">",
"           Nail-patella syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22472\">",
"           Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/55/12154\">",
"           Primary hyperoxaluria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/41/2712\">",
"           Renal cystic diseases in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28487\">",
"           Renal ectopic and fusion anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/43/10935\">",
"           Renal hypoplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/26/4520\">",
"           Renal involvement in the mitochondrial cytopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/51/35641\">",
"           Uncommon causes of congenital adrenal hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/10/5287\">",
"           Williams-Beuren syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/51/35641\">",
"           Uncommon causes of congenital adrenal hyperplasia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fluid and electrolyte disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/11/6330\">",
"           Approach to the child with metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25848\">",
"           Causes, diagnosis, and evaluation of hyperkalemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/33/3607\">",
"           Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41480\">",
"           Clinical features and diagnosis of diabetic ketoacidosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21048\">",
"           Clinical manifestations and causes of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/2/21545\">",
"           Clinical manifestations and causes of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/16/44295\">",
"           Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/22/17768\">",
"           Etiology and clinical manifestations of renal tubular acidosis in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/48/11018\">",
"           General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5337\">",
"           Hypernatremia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6470\">",
"           Maintenance fluid therapy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4279\">",
"           Management of hyperkalemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/15/18681\">",
"           Oral rehydration therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/46/7913\">",
"           Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27288\">",
"           Simple and mixed acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21526\">",
"           The ������anion gap/������HCO3 ratio in patients with a high anion gap metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7626\">",
"           Treatment and complications of diabetic ketoacidosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/31/505\">",
"           Treatment of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/17/17688\">",
"           Treatment of hypovolemia (dehydration) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24071\">",
"           Treatment of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11558\">",
"           Urine anion and osmolal gaps in metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6691\">",
"           Urine output in diabetes insipidus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glomerular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25974\">",
"           Complications of idiopathic nephrotic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/6/41066\">",
"           Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37432\">",
"           Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7288\">",
"           Evaluation and management of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/62/11238\">",
"           Evaluation of a child with glomerular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/1/12311\">",
"           Overview of the pathogenesis and causes of glomerulonephritis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/39/1657\">",
"           Pathophysiology and etiology of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/30/35304\">",
"           Poststreptococcal glomerulonephritis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/54/21354\">",
"           Steroid-resistant idiopathic nephrotic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/33/6679\">",
"           Symptomatic management of nephrotic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/15/28922\">",
"           Treatment of idiopathic nephrotic syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemolytic-uremic syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/52/43849\">",
"           Atypical hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35704\">",
"           Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30649\">",
"           Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/21/25943\">",
"           Ambulatory blood pressure monitoring in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17241\">",
"           Approach to hypertensive emergencies and urgencies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15878\">",
"           Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/45/17113\">",
"           Definition and diagnosis of hypertension in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/7/42105\">",
"           Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/60/37833\">",
"           Etiology, clinical features, and diagnosis of neonatal hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/42/2729\">",
"           Evaluation of hypertension in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9159\">",
"           Genetic factors in the pathogenesis of essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/37/44630\">",
"           Hypertension in infants between one month and one year of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/59/42936\">",
"           Management of hypertension in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32954\">",
"           The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/62/27626\">",
"           Treatment of hypertension in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nephrolithiasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/41/38552\">",
"           Acute management of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13623\">",
"           Clinical features and diagnosis of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/60/6090\">",
"           Epidemiology of and risk factors for nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26356\">",
"           Nephrocalcinosis in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/62/19432\">",
"           Prevention of recurrent nephrolithiasis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7288\">",
"           Evaluation and management of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/39/1657\">",
"           Pathophysiology and etiology of edema in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22154\">",
"           Complications of renal transplantation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/63/23543\">",
"           General principles of kidney transplantation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38394\">",
"           Immunosuppression in renal transplantation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40680\">",
"           Outcomes of renal transplantation in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary abnormalities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1127\">",
"           Evaluation of gross hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/1/27674\">",
"           Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26360\">",
"           Epidemiology and risk factors for urinary tract infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/62/41961\">",
"           Management of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/10/3242\">",
"           Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/59/14264\">",
"           Urinary tract infections in newborns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24966\">",
"           Clinical manifestations and initial management of infants with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/7/28793\">",
"           Etiology and clinical features of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25384\">",
"           Evaluation and diagnosis of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/51/41785\">",
"           Management of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/20/34119\">",
"           Postnatal management of antenatal hydronephrosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-AE08838B38-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_41_19088=[""].join("\n");
var outline_f18_41_19088=null;
var title_f18_41_19089="Flow propagation velocity";
var content_f18_41_19089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of flow propagation velocity measurement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Sherif F Nagueh.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19089=[""].join("\n");
var outline_f18_41_19089=null;
var title_f18_41_19090="Sagittal airway 20 week fetus";
var content_f18_41_19090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sagittal airway 20 week fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     e: epiglotis; l: larynx; t: trachea; l: lung; h: heart.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19090=[""].join("\n");
var outline_f18_41_19090=null;
var title_f18_41_19091="Cutaneous innervation from cervical plexus";
var content_f18_41_19091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Cutaneous innervation from cervical plexus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 622px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cervical plexus supplies the skin of the anterior and lateral neck, and scalp, as well as the muscles of the neck including the scalenes and strap muscles. It also innervates the diaphragm via the phrenic nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19091=[""].join("\n");
var outline_f18_41_19091=null;
var title_f18_41_19092="Famotidine, calcium carbonate, and magnesium hydroxide: Patient drug information";
var content_f18_41_19092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Famotidine, calcium carbonate, and magnesium hydroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32695?source=see_link\">",
"     see \"Famotidine, calcium carbonate, and magnesium hydroxide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pepcid&reg; Complete&reg; [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Dual Action [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pepcid&reg; Complete&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to famotidine, calcium carbonate, magnesium hydroxide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels or kidney stones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other drugs for heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid foods that make your heartburn worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696905",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug for more than 2 weeks unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698715",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you need to use this drug more than 14 days in a row.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than 2 tablets a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chew or crush tablet well. Mix crushed tablet with food. Do not swallow tablet whole.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12463 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19092=[""].join("\n");
var outline_f18_41_19092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170010\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170011\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019307\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019309\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019308\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019313\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019314\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019316\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019311\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019312\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019317\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019318\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32695?source=related_link\">",
"      Famotidine, calcium carbonate, and magnesium hydroxide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_41_19093="Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients";
var content_f18_41_19093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19093/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19093/contributors\">",
"     James H Shelhamer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19093/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19093/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19093/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19093/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/41/19093/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection can present with fever, dyspnea, hypoxemia, and a chest radiograph showing diffuse pulmonary infiltrates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=see_link\">",
"     \"Approach to the HIV-infected patient with pulmonary symptoms\"",
"    </a>",
"    .) Even in the era of highly active antiretroviral therapy, the most common etiologies of pneumonia in this setting are still Pneumocystis carinii (renamed P. jirovecii); bacteria and a variety of other entities also enter the differential diagnosis, including cytomegalovirus pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cytomegalovirus (CMV) may produce serious sequelae and death among organ transplant recipients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    ), its significance as a pulmonary pathogen in HIV-infected patients is often unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/3\">",
"     3",
"    </a>",
"    ]. The data regarding CMV as a pulmonary pathogen in patients with HIV infection and the prognosis and efficacy of treatment of CMV-related pulmonary disease in this setting will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AUTOPSY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy studies are the most abundant source of evidence for CMV as a cause of pulmonary disease in HIV-infected patients. In a study of 75 autopsies of patients with HIV infection, 38 of whom were thought to have died of respiratory failure, 44 patients (59 percent) had histologic evidence of CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/4\">",
"     4",
"    </a>",
"    ]. In over one-half of these patients, the CMV was thought to cause little or no pulmonary dysfunction. In contrast, CMV was thought to play some role in 21 of the 44 patients (as a sole pathogen in 6 patients and as a contributory pathogen in 15).",
"   </p>",
"   <p>",
"    In another study of 54 patients who died with HIV infection, 31 patients (57 percent) had histologic evidence of CMV infection in the lung found at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/5\">",
"     5",
"    </a>",
"    ]. One half of the patients with evidence for CMV pneumonitis were thought to have died of respiratory failure, although other causative agents were also found in most of these patients.",
"   </p>",
"   <p>",
"    Therefore, histologic evidence of CMV pneumonitis is frequently present at autopsy in HIV-infected patients, but CMV is not commonly found as the sole pathogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is whether CMV causes pneumonia in patients with less advanced HIV infection than is the case with the aforementioned autopsy studies. One study compared the clinical features of subjects with lung biopsy documented HIV-related CMV pneumonia to those of subjects with HIV-related PCP. Subjects with CMV pneumonia were more likely to have low CD4 counts (below 12",
"    <span class=\"nowrap\">",
"     cells/microL),",
"    </span>",
"    again suggesting that CMV pneumonia occurs primarily with advanced HIV infection and severe immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the clinical setting, the possibility of pulmonary infection with CMV arises because of one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive CMV culture of bronchoalveolar lavage fluid (BAL)",
"     </li>",
"     <li>",
"      Evidence of CMV antigens or typical cytopathic changes induced by CMV seen on cytologic examination of BAL fluid cells",
"     </li>",
"     <li>",
"      Transbronchial or surgical lung biopsy demonstrating pneumonitis and cytopathic effect consistent with CMV",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage fluid culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures of BAL fluid are not established as either a sensitive or a specific test for CMV pneumonitis. Reports of the sensitivity of the technique are variable; one study of 54 patients with CMV pneumonitis at autopsy found a sensitivity of BAL culture of only 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/5\">",
"     5",
"    </a>",
"    ], while a second study involving 40 autopsies found a sensitivity of 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/7\">",
"     7",
"    </a>",
"    ]. The specificity of a positive result appears unacceptably low, and the presence of CMV on BAL culture does not correlate with gas exchange or chest radiographic abnormalities, or with acute morbidity due to pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. One study of asymptomatic HIV-infected subjects showed that BAL culture was positive for CMV in 9 out of 19 subjects (47 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated the diagnostic yield of BAL in 420 HIV-infected patients with respiratory symptoms during two separate time periods before (1992-1996) and after (1997-2003) the introduction of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/11\">",
"     11",
"    </a>",
"    ]. Although fewer procedures were done in the latter period (130 versus 290), the frequency of positive CMV cultures in BAL samples was similar (28 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A particular problem is posed by the coexistence of CMV with other pathogens found in BAL fluid, particularly Pneumocystis jirovecii. BAL fluid cultures or PCR testing may be positive for CMV in the majority of HIV-infected patients with Pneumocystis jirovecii pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/9\">",
"     9",
"    </a>",
"    ], but it is not clear that clinical sequelae can be attributed to the presence of CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. As an example, in 111 patients with AIDS and a first episode of PCP, 48 percent had CMV demonstrated on BAL fluid culture [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/13\">",
"     13",
"    </a>",
"    ]. There was no difference between CMV culture-positive and culture-negative patients in terms of initial presentation, long-term survival, hospital mortality, or length of hospital stay. Another study even suggested a better short-term survival and a lower incidence of early deterioration in oxygenation in those patients with PCP who also had BAL cultures positive for CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAL cytology that is positive for a cytopathic effect is presumably a more specific test than is BAL fluid culture or PCR for CMV. However, there is no good correlation of cytopathic effect with either pneumonia attributable to HIV or with morbidity, above and beyond that associated with the presence of a positive BAL culture [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/15\">",
"     15",
"    </a>",
"    ]. Transbronchial biopsies are likely to be more specific for CMV pneumonitis, but are almost certainly insensitive due to the patchy nature of the disease (",
"    <a class=\"graphic graphic_picture graphicRef50365 \" href=\"UTD.htm?26/26/27048\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROGNOSTIC IMPLICATIONS OF PULMONARY CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of CMV in BAL fluid by culture or cytopathic effect connotes a poor prognosis for long-term survival. This phenomenon may reflect CMV shedding as a marker for deteriorating immune system function, or may be due to an effect of CMV itself. For example, one report examined the three and six month mortality in 74 patients with evidence of CMV in BAL specimens compared with 40 patients without evidence of CMV in BAL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/15\">",
"     15",
"    </a>",
"    ]. The patients with evidence of CMV had a higher mortality at both three (25 versus 10 percent) and six months (50 versus 15 percent). The difference in mortality between the two groups was not directly attributable to lower CD4 counts or P. carinii infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECT OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central question in the care of HIV-infected patients with pneumonia and isolation of CMV is whether anti-CMV therapy improves outcome. The preponderance of data suggest that anti-CMV treatment of HIV-infected patients with pneumonia and BAL cultures positive for CMV is not associated with improved survival in comparison with patients who have positive BAL cultures for CMV but are not treated with anti-CMV therapy. For example, one study identified 98 patients with PCP, 26 of whom also had CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/16\">",
"     16",
"    </a>",
"    ]. Thirteen of the 26 patients with both pathogens received antiviral therapy in addition to anti-PCP therapy; no difference in short-term mortality resulted from anti-CMV therapy.",
"   </p>",
"   <p>",
"    On the other hand, although efficacy is not firmly established, there are some data suggesting a benefit of treatment for patients with presumed isolated CMV pneumonitis. One study, for example, described the course in eight patients with CMV pneumonitis in whom no other pathogens were isolated from the respiratory tract despite an intensive search [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/17\">",
"     17",
"    </a>",
"    ]. The three untreated patients died of respiratory failure and had CMV pneumonitis confirmed at autopsy. The five treated patients demonstrated improvement, such that all were asymptomatic at three month follow-up. Two of the five treated patients died of other opportunistic infections within six months of the initiation of therapy. Another study reported a survival to hospital discharge of 10 of 17 patients (59 percent) treated for biopsy documented CMV pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use of steroids in the setting of CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The era of adjuvant corticosteroid therapy for HIV-infected patients with PCP has raised concerns that further suppression of host immunity by steroids may potentiate the growth and further dissemination of CMV. For example, one study of 148 consecutive patients with a first episode of PCP treated with adjuvant corticosteroids found that the presence of CMV in BAL fluid did not affect short-term mortality, but was associated with a twofold increase in mortality at three months compared to those patients with negative cultures for CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/18\">",
"     18",
"    </a>",
"    ]. A separate retrospective study of patients treated for severe PCP with adjuvant corticosteroids suggested that patients with BAL cultures positive for CMV had an increased in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antiviral regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) is currently considered the drug of choice, although its efficacy for CMV pneumonitis in HIV-infected patients has not been established by controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/6,20,21\">",
"     6,20,21",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     \"Ganciclovir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    is considered an alternative therapy, although data for its use in this setting are sparse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The efficacy of intravenous immunoglobulin therapy or CMV hyperimmune globulin in this patient population is unknown. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     \"Foscarnet: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the basis of current data, the following points and recommendations can be made about pulmonary CMV in HIV-infected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CMV as a sole cause of pneumonia is not common at least until the late stages of HIV disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19093/abstract/4,5,23\">",
"       4,5,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      BAL culture or PCR is not a specific test for CMV pneumonitis.",
"     </li>",
"     <li>",
"      Treatment of CMV is recommended in the presence of symptomatic pulmonary disease, evidence of CMV in the lung, and the absence of other treatable pulmonary infections.",
"     </li>",
"     <li>",
"      Treatment of asymptomatic persons with evidence of pulmonary CMV is not recommended.",
"     </li>",
"     <li>",
"      Treatment of CMV when concomitant pathogens are present is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/1\">",
"      Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/2\">",
"      Rimland D, Navin TR, Lennox JL, et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002; 16:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/3\">",
"      Baughman RP. Cytomegalovirus: the monster in the closet? Am J Respir Crit Care Med 1997; 156:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/4\">",
"      McKenzie R, Travis WD, Dolan SA, et al. The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases. Medicine (Baltimore) 1991; 70:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/5\">",
"      Wallace JM, Hannah J. Cytomegalovirus pneumonitis in patients with AIDS. Findings in an autopsy series. Chest 1987; 92:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/6\">",
"      Salomon N, Gomez T, Perlman DC, et al. Clinical features and outcomes of HIV-related cytomegalovirus pneumonia. AIDS 1997; 11:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/7\">",
"      Uberti-Foppa C, Lillo F, Terreni MR, et al. Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease. Chest 1998; 113:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/8\">",
"      Millar AB, Patou G, Miller RF, et al. Cytomegalovirus in the lungs of patients with AIDS. Respiratory pathogen or passenger? Am Rev Respir Dis 1990; 141:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/9\">",
"      Miles PR, Baughman RP, Linnemann CC Jr. Cytomegalovirus in the bronchoalveolar lavage fluid of patients with AIDS. Chest 1990; 97:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/10\">",
"      Mann M, Shelhamer JH, Masur H, et al. Lack of clinical utility of bronchoalveolar lavage cultures for cytomegalovirus in HIV infection. Am J Respir Crit Care Med 1997; 155:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/11\">",
"      Joos L, Chhajed PN, Wallner J, et al. Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunocompromised patients. Respir Med 2007; 101:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/12\">",
"      Clarke JR, Fleming J, Donegan K, et al. Effect of HIV-1 and cytomegalovirus in bronchoalveolar lavage cells on the transfer factor for lung carbon monoxide in AIDS patients. AIDS 1991; 5:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/13\">",
"      Jacobson MA, Mills J, Rush J, et al. Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection. Am Rev Respir Dis 1991; 144:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/14\">",
"      Bozzette SA, Arcia J, Bartok AE, et al. Impact of Pneumocystis carinii and cytomegalovirus on the course and outcome of atypical pneumonia in advanced human immunodeficiency virus disease. J Infect Dis 1992; 165:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/15\">",
"      Hayner CE, Baughman RP, Linnemann CC Jr, Dohn MN. The relationship between cytomegalovirus retrieved by bronchoalveolar lavage and mortality in patients with HIV. Chest 1995; 107:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/16\">",
"      Bower M, Barton SE, Nelson MR, et al. The significance of the detection of cytomegalovirus in the bronchoalveolar lavage fluid in AIDS patients with pneumonia. AIDS 1990; 4:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/17\">",
"      Waxman AB, Goldie SJ, Brett-Smith H, Matthay RA. Cytomegalovirus as a primary pulmonary pathogen in AIDS. Chest 1997; 111:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/18\">",
"      Jensen AM, Lundgren JD, Benfield T, et al. Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution. Chest 1995; 108:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/19\">",
"      Hyland M, Chan M, Hyland RH, Chan CK. Associating poor outcome with the presence of cytomegalovirus in bronchoalveolar lavage from HIV patients with Pneumocystis carinii pneumonia. Chest 1995; 107:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/20\">",
"      Rodriguez-Barradas MC, Stool E, Musher DM, et al. Diagnosing and treating cytomegalovirus pneumonia in patients with AIDS. Clin Infect Dis 1996; 23:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/21\">",
"      Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med 1988; 108:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/22\">",
"      Youle M, Chanas A, Gazzard B. Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study. J Infect 1990; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19093/abstract/23\">",
"      Wallace JM, Rao AV, Glassroth J, et al. Respiratory illness in persons with human immunodeficiency virus infection. The Pulmonary Complications of HIV Infection Study Group. Am Rev Respir Dis 1993; 148:1523.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3713 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19093=[""].join("\n");
var outline_f18_41_19093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AUTOPSY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bronchoalveolar lavage fluid culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other specimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROGNOSTIC IMPLICATIONS OF PULMONARY CMV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECT OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use of steroids in the setting of CMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antiviral regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3713\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3713|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/26/27048\" title=\"picture 1\">",
"      CMV pneumonitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=related_link\">",
"      Approach to the HIV-infected patient with pulmonary symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=related_link\">",
"      Foscarnet: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=related_link\">",
"      Ganciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_41_19094="Vegetative pyoderma gangrenosum";
var content_f18_41_19094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Vegetative pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An ulcer with a verrucous surface is present on the ankle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19094=[""].join("\n");
var outline_f18_41_19094=null;
var title_f18_41_19095="Prognosis and treatment of mixed connective tissue disease";
var content_f18_41_19095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and treatment of mixed connective tissue disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19095/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19095/contributors\">",
"     Robert M Bennett, MD, FRCP, MACR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19095/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19095/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19095/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19095/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/41/19095/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed connective tissue disease (MCTD) is a generalized connective tissue disorder that includes clinical features commonly seen in systemic lupus erythematosus (SLE), scleroderma, and polymyositis (referred to as overlap syndrome) (",
"    <a class=\"graphic graphic_table graphicRef68985 \" href=\"UTD.htm?11/44/11980\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/1\">",
"     1",
"    </a>",
"    ]. Almost any organ system can be involved in MCTD. There are, however, several clinical features that, taken together, suggest the presence of MCTD rather than another connective tissue disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Raynaud phenomenon and swollen hands or puffy fingers",
"     </li>",
"     <li>",
"      A high titer speckled pattern ANA (usually &ge;1280)",
"     </li>",
"     <li>",
"      The absence of severe renal and central nervous system (CNS) disease",
"     </li>",
"     <li>",
"      More severe arthritis, which is sometimes deforming",
"     </li>",
"     <li>",
"      The development of pulmonary arterial hypertension (PAH), which differentiates MCTD from both SLE and scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autoantibodies whose fine specificity is anti-U1 RNP, especially antibodies to the 70 kD protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link\">",
"     \"Clinical manifestations of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of MCTD does not require the simultaneous presence of overlap features. It is, in fact, unusual for patients to exhibit overlapping features in the early stages of MCTD, but distinctive clinical characteristics of SLE, scleroderma, and polymyositis commonly appear sequentially over time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=see_link\">",
"     \"Definition and diagnosis of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the prognosis and treatment of MCTD. The typically better prognosis in this disorder than that in other connective tissue diseases is another of its characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original description of patients with MCTD emphasized the relatively good prognosis and excellent response to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/3\">",
"     3",
"    </a>",
"    ]. As noted above, these patients have a low prevalence of serious renal disease and life-threatening neurologic problems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Although both of these organ systems are involved in about 25 percent of patients, the renal disease is usually a fairly benign form of membranous nephropathy, while CNS involvement is most commonly a bothersome, but not life-threatening, trigeminal neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are clearly subsets of patients who are at risk for significant morbidity and mortality. In a follow-up report of the original 25 patients, for example, nine (36 percent) required repeated courses of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, in a second study of 47 patients followed for 3 to 29 years, pulmonary hypertension was the underlying cause of death in 6 of 11 patients who died [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/7\">",
"     7",
"    </a>",
"    ]; five of the patients who died had IgG anticardiolipin antibodies, a possible risk factor for severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall mortality is apparently lower in patients with MCTD than in those with classic SLE. Nevertheless, there is appreciable mortality associated with MCTD ranging, in different studies, from 16 to 28 percent at 10 to 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Those patients with more features of scleroderma and polymyositis have a worse prognosis (67 percent mortality at 10 years in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major causes of death include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive pulmonary arterial hypertension (PAH) and its cardiac complications [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/7,15\">",
"       7,15",
"      </a>",
"      ]. In some cases, PAH due to scleroderma-like vasculopathy can lead to death in a few weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Renovascular hypertension and cerebral hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity is quite high in patients with MCTD. The quality of life may be reduced due to multiple factors including recurrent musculoskeletal pain, low energy levels, and the stress of living with a potentially fatal condition. Flares of polymyositis, pericarditis, pleurisy, and myocarditis are usually treated with fairly high-dose steroids for several months. As a result, patients may suffer from the many consequences of extended glucocorticoid use, including aseptic necrosis, vertebral compression fractures, cataracts, weight gain, accelerated atherosclerosis, nosocomial infections, and proximal myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other problems can also be debilitating:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in patients with SLE, it is not uncommon for patients with MCTD to develop the widespread pain syndrome of fibromyalgia. This can often become more debilitating than the primary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with severe Raynaud phenomena can develop ischemic ulcers and even outright gangrene of the fingers. Such patients generally have a higher mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small subset of patients with MCTD develops a deforming arthritis and even arthritis mutilans [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Esophageal dysmotility can progress over time; as a result, some patients must undergo regular bougie dilatation. Gastroesophageal acid reflux may lead to Barrett's esophagus and, eventually, to carcinoma.",
"     </li>",
"     <li>",
"      A minority of patients with renal disease develops end-stage renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients diagnosed with MCTD may also evolve into a clinical picture more consistent with SLE, scleroderma, or rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/14,26,27\">",
"     14,26,27",
"    </a>",
"    ]. Such an evolution is, in part, genetically predetermined. Particular HLA-DR alleles have been associated with a propensity to develop one connective disease as opposed to another. As an example, SLE is more likely in patients with HLA-DR3, scleroderma with HLA-DR5, and MCTD with HLA-DR4 or HLA-DR2 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=see_link\">",
"     \"Anti-U1 RNP antibodies in mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although MCTD was originally described as being extremely responsive to glucocorticoids, it is thought to be incurable. In addition, no controlled trials have been performed to guide therapy. Instead, the management of patients with MCTD generally rests upon the known effectiveness of specific therapies for similar problems seen in SLE, scleroderma, or polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general review of the treatments for particular features of MCTD is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef63295 \" href=\"UTD.htm?28/53/29533\">",
"     table 2",
"    </a>",
"    ). More complete and detailed discussions are provided elsewhere. (See the appropriate topic review for a given manifestation.) The following discussion outlines some specific management issues and empiric observations concerning therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, those features of MCTD also observed among patients with systemic lupus erythematosus (eg, pleurisy, pericarditis) respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 0.25 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. By comparison, scleroderma-like features (eg, Raynaud phenomenon, pulmonary hypertension) are usually less responsive to therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"       \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=see_link\">",
"       \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since pulmonary arterial hypertension (PAH) is the main cause of death among patients with MCTD, early diagnosis with routine echocardiography is recommended for all patients. The MCTD Research Committee or the European Society of Cardiology has recommended that the threshold for the estimated pulmonary arterial systolic pressure for the diagnosis of PAH be set at 36 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/29\">",
"       29",
"      </a>",
"      ]. The timely diagnosis of PAH will hopefully lead to its early treatment with the administration of therapies which have shown some promise in this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/30\">",
"       30",
"      </a>",
"      ]. These therapies include a calcium channel blocker (usually long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ), anticoagulation, intravenous prostacyclin, prolonged immunosuppression (beginning with glucocorticoids and combining with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      if necessary), and angiotensin converting enzyme inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/31-38\">",
"       31-38",
"      </a>",
"      ]. In end-stage disease, a heart-lung transplant needs to be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/39\">",
"       39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Advances in the treatment of pulmonary arterial hypertension have led to reduced morbidity and mortality. Long-term treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      or prostacyclin improves exercise capacity, hemodynamics, and survival in most patients.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"       Bosentan",
"      </a>",
"      , an oral endothelin-1 antagonist, and phosphodiesterase inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      are proving useful in the management of this complication [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. Treatment of pulmonary hypertension in patients with connective tissue disease is discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"       \"Treatment of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many of the clinical manifestations of MCTD associated with significant morbidity tend to be intermittent and responsive to glucocorticoids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day); these disorders include aseptic meningitis, myositis, pleurisy, pericarditis, and myocarditis. By comparison, nephrotic syndrome, Raynaud phenomenon, deforming arthropathy, acrosclerosis, and peripheral neuropathies are usually steroid resistant.",
"     </li>",
"     <li>",
"      Due to the risk of inducing ventricular arrhythmias, digitalis is relatively contraindicated in patients with myocarditis. In addition, antimalarial drugs should be used with caution in those with a fascicular or bundle branch block because of the risk of inducing complete heart block [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many gastrointestinal problems can be managed according to the treatment guidelines established for similar disorders in scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11415?source=see_link\">",
"       \"Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      , however, may be effective in the treatment of esophageal involvement. As an example, a longitudinal study of 10 patients with MCTD evaluated the effectiveness of prednisone (an average dose of 25",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in the treatment of esophageal dysmotility [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/44\">",
"       44",
"      </a>",
"      ]. Significant improvement was demonstrated in lower esophageal sphincter pressure, and a trend toward improvement was noted in proximal esophageal peristaltic waves.",
"     </li>",
"     <li>",
"      As in SLE, it is worthwhile considering the use of intravenous immune globulin (IVIG) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      in patients with steroid resistant thrombocytopenia or hemolytic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link\">",
"       \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous immune globulin (IVIG) may also have a role in the treatment of severe, eruptive skin disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/48\">",
"       48",
"      </a>",
"      ] and of steroid resistant myositis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link\">",
"       \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with severe hand deformities may be helped by soft tissue release operations and selected joint fusions.",
"     </li>",
"     <li>",
"      As in SLE and other autoimmune disorders, the combination of systemic inflammation, anti-endothelial antibodies, and hyperlipidemia (often aggravated by glucocorticoid therapy) may lead to long-term morbidity or mortality from accelerated atherosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Concerns with glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since MCTD was initially considered to be a steroid responsive disease, there is often a tendency to assume that all patients with MCTD should be treated with long-term glucocorticoids. This mistake is compounded by the assumption that all medical problems are related to MCTD. As an example, apparent flares of discomfort and pain in MCTD may instead be due to myofascial pain syndrome or to fibromyalgia and are, therefore, unresponsive to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition, malaise and easy fatigability may be due to a reactive depression or to a lack of conditioning. As a result, the management of patients with MCTD requires continuing reassessment of the changing pattern of disease activity and a constant alertness to the emergence of new problems.",
"   </p>",
"   <p>",
"    As with other connective tissue diseases, the onset of an iatrogenic illness needs to be considered in the differential diagnosis of any new clinical problem. Over time, concern usually mounts over the total glucocorticoid burden and the possibility of inducing an iatrogenic steroid myopathy, nosocomial infection, aseptic necrosis of bone, or accelerated osteoporosis. Thus, among patients requiring long-term glucocorticoids, the use of antimalarials (400 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (7.5 to 15",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    may be reasonable in an attempt to minimize the cumulative steroid burden. In one study of patients with SLE, for example, withdrawing hydroxychloroquine in stable patients was associated with a 2.5-fold increase in the risk of a clinical flare compared with those maintained on hydroxychloroquine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19095/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unless contraindicated, all steroid-treated patients should take calcium and vitamin D supplements. Postmenopausal women or others at high risk for osteoporosis may benefit from assessment of bone mineral density and use of bisphosphonates or other prophylactic or therapeutic interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .) Anecdotal experience suggests that",
"    <span class=\"nowrap\">",
"     estrogen/progesterone",
"    </span>",
"    therapy is not associated with flares of MCTD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10067795\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mixed connective tissue disease (MCTD) have a quite variable prognosis. Some features (eg, pleurisy, aseptic meningitis) are responsive to glucocorticoids, while scleroderma-like features, especially pulmonary hypertension, are steroid unresponsive. There is a low prevalence of serious renal disease and life-threatening neurologic problems. Although the kidneys or nervous system are affected in about 25 percent of patients, the renal disease is usually a fairly benign form of membranous nephropathy, and the most common CNS manifestation is trigeminal neuropathy. Anticardiolipin antibodies may be a risk factor for more severe disease, including pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimates of mortality in patients with MCTD range from 16 to 28 percent at 10 to 12 years. Patients with more features of scleroderma and polymyositis have a worse prognosis. The major causes of death include progressive pulmonary hypertension and its cardiac complications, myocarditis, renovascular hypertension, and cerebral hemorrhage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a high level of morbidity in patients with MCTD. Contributing factors include recurrent musculoskeletal pain, low energy levels, psychological stress, and the multiple adverse effects of periodic and relatively high doses of glucocorticoids. Other problems include fibromyalgia, severe Raynaud phenomena with ischemic changes, deforming arthritis, esophageal dysmotility, gastroesophageal reflux (sometimes resulting in Barrett esophagus), and, infrequently, end-stage renal disease. Patients with MCTD may also evolve into a clinical picture more consistent with SLE, scleroderma, or rheumatoid arthritis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MCTD is thought to be incurable, and no randomized trials have been performed to guide therapy. The management is largely guided by the known effectiveness of specific therapies for similar problems seen in SLE, scleroderma, or polymyositis. Many of the clinical manifestations of MCTD associated with significant morbidity, such as aseptic meningitis, myositis, pleurisy, pericarditis, and myocarditis, tend to be intermittent and responsive to glucocorticoids. Glucocorticoids may occasionally be effective in MCTD for esophageal involvement. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We give particular attention to the avoidance of adverse effects related to the use of glucocorticoids. For example, features of fibromyalgia, a mood disorder, or deconditioning should be distinguished from manifestations of active MCTD that may require glucocorticoids. Appropriate measures should be taken to prevent glucocorticoid-induced osteoporosis. Antimalarials or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      should be used in patients requiring repeated or ongoing treatment with glucocorticoids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Concerns with glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bennett, RM. Overlap Syndromes. In: Textbook of Rheumatology, 8th ed, Firestein (Ed), W.B. Saunders Co, Philadelphia 2009. p.1381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/2\">",
"      Hoffman RW, Maldonado ME. Immune pathogenesis of Mixed Connective Tissue Disease: a short analytical review. Clin Immunol 2008; 128:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/3\">",
"      Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/4\">",
"      Piirainen HI, Kurki PT. Clinical and serological follow-up of patients with polyarthritis, Raynaud's phenomenon, and circulating RNP antibodies. Scand J Rheumatol 1990; 19:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/5\">",
"      Piirainen HI. Patients with arthritis and anti-U1-RNP antibodies: a 10-year follow-up. Br J Rheumatol 1990; 29:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/6\">",
"      Sharp GC, Anderson PC. Current concepts in the classification of connective tissue diseases. Overlap syndromes and mixed connective tissue disease (MCTD). J Am Acad Dermatol 1980; 2:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/7\">",
"      Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/8\">",
"      Aringer M, Smolen JS. Mixed connective tissue disease: what is behind the curtain? Best Pract Res Clin Rheumatol 2007; 21:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/9\">",
"      Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976; 295:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/10\">",
"      Bennett RM, Spargo BH. Immune complex nephropathy in mixed connective tissue disease. Am J Med 1977; 63:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/11\">",
"      Bennett RM, Bong DM, Spargo BH. Neuropsychiatric problems in mixed connective tissue disease. Am J Med 1978; 65:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/12\">",
"      Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980; 59:239.",
"     </a>",
"    </li>",
"    <li>",
"     Miyawaki S, Onodera H. Clinical course and prognosis of patients with mixed connective tissue disease. In: Mixed Connective Tissue Disease and Antinuclear Antibodies, Kasukawa R, Sharp G (Eds), Excerpta Medica, Amsterdam 1987. p.331.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/14\">",
"      Gendi NS, Welsh KI, Van Venrooij WJ, et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995; 38:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/15\">",
"      Hant FN, Herpel LB, Silver RM. Pulmonary manifestations of scleroderma and mixed connective tissue disease. Clin Chest Med 2010; 31:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/16\">",
"      Bennett RM, O'Connell DJ. Mixed connective tisssue disease: a clinicopathologic study of 20 cases. Semin Arthritis Rheum 1980; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/17\">",
"      Lundberg IE. Cardiac involvement in autoimmune myositis and mixed connective tissue disease. Lupus 2005; 14:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/18\">",
"      Graf WD, Milstein JM, Sherry DD. Stroke and mixed connective tissue disease. J Child Neurol 1993; 8:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/19\">",
"      Kuwana M, Kaburaki J, Okano Y, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/20\">",
"      Morand EF, Miller MH, Whittingham S, Littlejohn GO. Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. Lupus 1994; 3:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/21\">",
"      Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994; 37:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/22\">",
"      Bennett RM, O'Connell DJ. The arthritis of mixed connective tissue disease. Ann Rheum Dis 1978; 37:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/23\">",
"      Halla JT, Hardin JG. Clinical features of the arthritis of mixed connective tissue disease. Arthritis Rheum 1978; 21:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/24\">",
"      Ramos-Niembro F, Alarc&oacute;n-Segovia D, Hern&aacute;ndez-Ort&iacute;z J. Articular manifestations of mixed connective tissue disease. Arthritis Rheum 1979; 22:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/25\">",
"      Kitridou RC, Akmal M, Turkel SB, et al. Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study. Semin Arthritis Rheum 1986; 16:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/26\">",
"      Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/27\">",
"      De Clerck LS, Meijers KA, Cats A. Is MCTD a distinct entity? Comparison of clinical and laboratory findings in MCTD, SLE, PSS, and RA patients. Clin Rheumatol 1989; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/28\">",
"      Kim P, Grossman JM. Treatment of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/29\">",
"      Yoshida S. Pulmonary arterial hypertension in connective tissue diseases. Allergol Int 2011; 60:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/30\">",
"      Fares WH, Trow TK. Targeted approaches to the treatment of pulmonary hypertension. Ther Adv Respir Dis 2012; 6:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/31\">",
"      Ueda Y, Yamauchi Y, Makizumi K, et al. Successful treatment of acute right cardiac failure due to pulmonary thromboembolism in mixed connective tissue disease. Jpn J Med 1991; 30:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/32\">",
"      Dahl M, Chalmers A, Wade J, et al. Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J Rheumatol 1992; 19:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/33\">",
"      Sullivan WD, Hurst DJ, Harmon CE, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984; 63:92.",
"     </a>",
"    </li>",
"    <li>",
"     Sharp GC. Therapy and prognosis of MCTD. In: Mixed Connective Tissue Disease and Antinuclear Antibodies, Kasukawa R, Sharp G (Eds), Excerpta Medica, Amsterdam 1987. p.315.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/35\">",
"      Alpert MA, Pressly TA, Mukerji V, et al. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 1991; 68:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/36\">",
"      McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/37\">",
"      Alpert MA, Pressly TA, Mukerji V, et al. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992; 102:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/38\">",
"      Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/39\">",
"      de Perrot M, Granton JT, McRae K, et al. Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. J Thorac Cardiovasc Surg 2012; 143:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/40\">",
"      V&eacute;gh J, So&oacute;s G, Csip&otilde; I, et al. Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol Int 2006; 26:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/41\">",
"      Naclerio C, D'Angelo S, Baldi S, et al. Efficacy of bosentan in the treatment of a patient with mixed connective tissue disease complicated by pulmonary arterial hypertension. Clin Rheumatol 2010; 29:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/42\">",
"      Verny C, de Gennes C, S&eacute;bastien P, et al. [Heart conduction disorders in long-term treatment with chloroquine. Two new cases]. Presse Med 1992; 21:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/43\">",
"      Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/44\">",
"      Pope JE. Other manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/45\">",
"      Francioni C, Galeazzi M, Fioravanti A, et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/46\">",
"      Sany J. Intravenous immunoglobulin therapy for rheumatic diseases. Curr Opin Rheumatol 1994; 6:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/47\">",
"      Chan AC, Sack K. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus. J Rheumatol 1991; 18:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/48\">",
"      Ulmer A, K&ouml;tter I, Pfaff A, Fierlbeck G. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J Am Acad Dermatol 2002; 46:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/49\">",
"      Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007; 28:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19095/abstract/50\">",
"      A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991; 324:150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7555 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19095=[""].join("\n");
var outline_f18_41_19095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10067795\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Concerns with glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10067795\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7555\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7555|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/44/11980\" title=\"table 1\">",
"      Diagnostic criteria in MCTD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/53/29533\" title=\"table 2\">",
"      Treatment of MCTD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=related_link\">",
"      Anti-U1 RNP antibodies in mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=related_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11415?source=related_link\">",
"      Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_41_19096="Marine toxins";
var content_f18_41_19096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Marine toxins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19096/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19096/contributors\">",
"     Erin N Marcus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19096/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19096/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19096/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19096/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19096/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/41/19096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As world travel and trade grow, physicians are increasingly likely to encounter patients suffering from marine toxins. The world's oceans harbor hundreds of different types of marine toxins, and the epidemiology and clinical manifestations of these toxins vary widely.",
"   </p>",
"   <p>",
"    Some of the marine toxins that physicians in the United States are most likely to encounter are reviewed here, including ciguatera, scombroid, paralytic shellfish poisoning, neurotoxic shellfish poisoning, diarrheic shellfish poisoning, pufferfish poisoning, and a few others (",
"    <a class=\"graphic graphic_table graphicRef59905 \" href=\"UTD.htm?23/61/24540\">",
"     table 1",
"    </a>",
"    ). Marine envenomations, such as coral abrasions and sea urchin injuries, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42408?source=see_link\">",
"     \"Marine envenomations from corals, sea urchins, fish, or stingrays\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CIGUATERA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Named by the Portuguese biologist Parra in 1771, ciguatera toxicity has existed in the tropics for centuries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/1\">",
"     1",
"    </a>",
"    ]. Some authors have speculated that Alexander the Great refused to let his troops eat fish because of ciguatera. More recently, Captain William Bligh described symptoms of ciguatera among his sailors on an expedition in 1789 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ciguatera poisoning accounts for more than half of the fish-related foodborne disease outbreaks in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/1\">",
"     1",
"    </a>",
"    ], and is the most common fish food poisoning in tropical coastal regions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/3\">",
"     3",
"    </a>",
"    ]. An estimated 20,000 to 50,000 people develop ciguatera each year throughout the world [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ciguatera is vastly underreported, but estimates of lifetime prevalence range from 7 percent in Puerto Rico [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/5\">",
"     5",
"    </a>",
"    ] to 70 percent in the Polynesian Islands [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/6\">",
"     6",
"    </a>",
"    ]. Most cases originate in the tropics and subtropics, between 35 degrees north latitude and 35 degrees south latitude. However, many cases of ciguatera also occur in temperate regions because of increasing tourism and fish exportation. Canada, for example, has an estimated 1,000 cases annually, with an average medical cost of $2,470 per case [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two cases of ciguatera poisoning reported in 2004 represent the first known cases caused by fish (barracuda) caught off the coast of South Carolina [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/7\">",
"     7",
"    </a>",
"    ]. The occurrence may be related to increasing water temperatures in temperate areas and migration of fish from known ciguatera-endemic areas.",
"   </p>",
"   <p>",
"    More than 400 different fish species have been associated with ciguatera. Reef-dwelling tropical fish such as barracuda, moray eel, amberjack, and certain types of grouper, mackerel, parrotfish, and red snapper are the most common sources of ciguatera toxicity. Rare cases exist of ciguatera occurring after the ingestion of temperate fish, including farm-raised salmon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/8\">",
"     8",
"    </a>",
"    ]. In general, however, ciguatera from nontropical fish is extremely rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ciguatera is caused by several distinct toxins, of which ciguatoxin is the best known. These toxins are formed by dinoflagellates of the genus Gambierdiscus, single-celled algae-like organisms that grow on and around coral reefs. Gambierdiscus toxicus, which produces ciguatoxin, tends to proliferate on denuded coral surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/9\">",
"     9",
"    </a>",
"    ]. There is concern that as more coral reefs die because of global warming, nutrient runoff, and construction, ciguatera may increase.",
"   </p>",
"   <p>",
"    The dinoflagellates are consumed by fish that do not appear to suffer ill effects from the toxin. Large, predatory fish concentrate the toxin in their organs and flesh, and thus are considered most risky to human health. Ciguatera toxin-containing fish does not taste, smell, or appear unusual. Cooking, marinating, freezing, and stewing fish does not destroy the toxins.",
"   </p>",
"   <p>",
"    Ciguatoxin is a lipid soluble, heat stable, acid resistant neurotoxin. It opens voltage-dependent sodium channels in cell membranes, triggering membrane depolarization. Maitotoxin, another ciguatera associated toxin, increases calcium ion influx through excitable membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"     10",
"    </a>",
"    ]. Scaritoxin increases the permeability of sodium channels and causes norepinephrine and acetylcholine release [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient affected with ciguatera frequently develops gastrointestinal symptoms, including vomiting, diarrhea, and abdominal cramping, beginning three to six hours after eating contaminated fish, but the incubation period may be up to 30 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Neurologic symptoms usually begin 3 to 72 hours after the meal. The neurologic symptoms can include paresthesias, painful teeth, painful urination, blurred vision, nerve palsies, and",
"    <span class=\"nowrap\">",
"     hot/cold",
"    </span>",
"    temperature reversal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/14\">",
"     14",
"    </a>",
"    ]. Cardiovascular symptoms include bradycardia, heart block, and hypotension.",
"   </p>",
"   <p>",
"    Symptoms vary according to locale. In Polynesia, patients often lack the gastrointestinal symptoms of ciguatera, while in the Caribbean, ciguatera usually initially presents as a gastroenteritis followed by a neurologic illness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic symptoms typically persist from a few days to several weeks. About 20 percent of patients have symptoms that persist for months; less than 2 percent have symptoms that last for years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/15\">",
"     15",
"    </a>",
"    ]. Ciguatera symptoms can recur up to six months later after drinking alcohol or caffeine or eating nuts or fish. Rare cases have been reported of patients developing symptoms years later after drinking alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several possible theories to explain the recurrent and late symptoms of ciguatera: receptor site memory may increase a late response; ciguatera may remain in the body in high concentrations for long periods of time after the original exposure; and subsequent exposures add to this quantity of toxin, worsening the reaction.",
"   </p>",
"   <p>",
"    A number of other symptoms have been associated with ciguatera:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic ciguatera can present as a neuropsychiatric illness with fatigue and malaise.",
"     </li>",
"     <li>",
"      Pruritic paresthesias are common in some Pacific islands [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ciguatera has been associated with premature labor and spontaneous abortion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ciguatera has been reported to cause painful ejaculation in an affected male, followed by dyspareunia in the previously unaffected female [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one case, a baby born by caesarean section two days after its mother developed ciguatera exhibited left sided facial palsy, possible hand myotonia, and respiratory distress symptoms that resolved within six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/9\">",
"     9",
"    </a>",
"    ]. In another case, ciguatera appeared to be transmitted by breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall ciguatera fatality rate is about 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/4,10,12,13,17\">",
"     4,10,12,13,17",
"    </a>",
"    ], with death usually due to cardiovascular collapse or respiratory failure. This wide range reflects both the variation in exposure (a dose effect) and the preparedness of the medical care system; mortality is low in areas of the world where the emergency",
"    <span class=\"nowrap\">",
"     medical/critical",
"    </span>",
"    care system is able to treat coma, bradycardia, or hypotension if it develops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ciguatera is based upon the history and clinical findings. There is no commercially available serum test for the toxin, but data from a pilot study of a neuroblastoma cell bioassay suggest this test may be effective in diagnosing acute ciguatera poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/18\">",
"     18",
"    </a>",
"    ]. Fish can be tested using a mouse bioassay and an IgG immunoassay, but these tests are costly and time consuming and are not widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/11\">",
"     11",
"    </a>",
"    ]. The Association of Official Analytical Chemists (AOAC) is evaluating a promising enzyme immunoassay (EIA), which is designed to detect contaminated fish in the field [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many tropical cultures, local inhabitants believe that contaminated fish will not fight back as hard as other fish, and that cats will refuse contaminated fish. However, these beliefs have never been borne out by scientific data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of ciguatera is supportive. Multiple uncontrolled trials have found that intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , given at a dose of 1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    reduces neurologic symptoms when given within the first 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the only randomized, placebo-controlled trial, conducted in 50 patients with ciguatera, found that treatment with a single intravenous dose of mannitol did not relieve signs and symptoms any better than intravenous normal saline, and was associated with increased discomfort from the infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/21\">",
"     21",
"    </a>",
"    ]. Significant improvement was seen in both treatment groups with equal frequency at 1, 3, and 24 hours after the infusion; the authors hypothesized that rapid infusion of either solution may have had a beneficial effect by diluting the toxin. Despite this lack of effect, many experts strongly recommend mannitol for acute ciguatera poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     Amitriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    have been reported to benefit ciguatera patients suffering from chronic fatigue, insomnia, and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    was reported to improve polyneuropathic symptoms in two patients, but it is an expensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be told to avoid all fish, alcohol, caffeine, and nuts for six months since these may trigger a recurrence of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients should also be informed that future attacks of ciguatera might be worse than the initial illness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"     10",
"    </a>",
"    ]. Ciguatera is not an infectious disease, and individuals do not develop immunity to the toxin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best way to prevent ciguatera is to avoid eating all high-risk fish, such as barracuda, moray eel, and certain types of grouper, red snapper, and amberjack. When in the tropics, it may be less risky to eat smaller fish and avoid eating fish organs where the toxin concentrates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/4\">",
"     4",
"    </a>",
"    ]. Recreational fishermen should also travel with experienced local guides who may know which areas are more risky [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SCOMBROID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scombroid fish poisoning is the most common seafood-associated disease in the United States, and together with ciguatera is one of the most common fish-related illnesses reported worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/26\">",
"     26",
"    </a>",
"    ]. Because of its clinical presentation it is frequently misdiagnosed as seafood allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scombroid is common throughout the world. Scombroid fish poisoning accounts for less than 0.5 percent of foodborne illnesses reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/27\">",
"     27",
"    </a>",
"    ]. Between 1998 and 2002, there were 167 outbreaks reported to the CDC in the United States that affected 703 persons, 38 of whom were hospitalized and none of whom died [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There were 181 confirmed cases of scombroid poisoning in New York State between the years 1980 and 1994, making it the most common toxin-induced fish-related illness in the state. Most of the cases were associated with tuna, bluefish, and mahi-mahi [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/28\">",
"     28",
"    </a>",
"    ]. Thirteen of these patients required hospitalization, more than for any seafood-associated illness in the state other than salmonella [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/28\">",
"     28",
"    </a>",
"    ]. Additional outbreaks of scombroid related to tuna steaks occurred in Louisiana and Tennessee in 2006 affecting a total of 15 persons [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scombroid often occurs in clusters. In one highly publicized case, 26 employees developed scombroid toxicity after eating blue marlin in the World Bank cafeteria in Washington, DC, in 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with ciguatera, scombroid is vastly underreported to health authorities and its true incidence is unknown. Underreporting is due to several factors: symptoms are of short duration and are often confused with other illnesses. Furthermore, reporting of individual cases is not mandatory under state or federal law [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scombroid occurs after consumption of contaminated dark meat fish. It is classically associated with finfish of the Scombroidae and Scomberesocidae families, such as tuna, mackerel, skip-jack, and bonito. An increase in scombroid poisoning cases in North Carolina was related to consumption of tuna burgers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/30\">",
"     30",
"    </a>",
"    ]. Scombroid poisoning also is not uncommon after ingestion of other types of fish, such as mahi-mahi (dolphin fish), bluefish, amberjack, swordfish, marlin, herring, sardines, anchovies, salmon, and trout [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/11,29\">",
"     11,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scombroid contamination is caused by bacterial overgrowth in improperly stored fish. Overgrowth can occur when the fish is stored at temperatures above 20&ordm;C for as little as two to three hours. Although more typically associated with fresh fish, scombroid poisoning can also occur with canned fish if the fish is handled improperly either before canning or after the can is opened; opened cans of tuna should be refrigerated to prevent poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/31\">",
"     31",
"    </a>",
"    ]. The bacteria are most commonly halophilic Vibrio species, Proteus, Klebsiella, Clostridium, Escherichia Coli, Salmonella species, and Shigella species, decarboxylate histidine, which is naturally present in the muscle of dark meat fish [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/26\">",
"     26",
"    </a>",
"    ]. Decarboxylation produces high levels of histamine and possibly other toxins.",
"   </p>",
"   <p>",
"    Toxins are not broken down by cooking, freezing, or subsequent refrigeration. Fish contaminated with scombroid may smell and appear fresh, although patients with scombroid often report that the fish tastes \"peppery,\" \"salty,\" or \"bubbly.\" Contamination of the fish frequently occurs when it is refrigerated inadequately at sea. Disease can occur even if the vendor selling the fish to the consumer stored the fish properly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of scombroid toxicity usually begin within an hour of eating contaminated fish. The symptoms resemble an IgE-mediated allergic reaction. The patient may suddenly experience flushing, a sensation of warmth, an erythematous rash, palpitations, and significant tachycardia. The rash often is especially prominent on the upper torso and face [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/26,32\">",
"     26,32",
"    </a>",
"    ]. Headache, blurred vision, respiratory distress, and dizziness have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scombroid poisoning usually resolves within 12 hours if untreated and has no long-term sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/12\">",
"     12",
"    </a>",
"    ]. However, elderly patients and individuals with pulmonary disease may have a more complicated course [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , which inhibits histamine metabolism, may be more vulnerable to scombroid poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of scombroid is usually clinical. If available, fish can be examined for histamine levels. Histamine levels greater than 100",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    grams of fish tissue are diagnostic of poisoning, while levels greater than 50",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    grams of fish are considered potentially toxic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One French report found plasma histamine levels ranging from 2 to 4 times the normal upper limit of 10.8",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    in five patients who presented within four hours after ingesting contaminated fish [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/33\">",
"     33",
"    </a>",
"    ]. The plasma histamine levels normalized at 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions to seafood can mimic scombroid poisoning. A blood test for IgE specific to the fish in question can be obtained to evaluate for possible fish allergy. Alternatively, the patient may be referred to an allergist for later skin testing and possible challenge to the fish in question. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16346?source=see_link&amp;anchor=H21#H21\">",
"     \"Seafood allergies: Fish and shellfish\", section on 'Scombroid poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scombroid poisoning usually responds rapidly to H1 antihistamines. Supportive care, including intravenous hydration, is also useful. Epinephrine and beta agonists may be given if bronchospasm or angioedema are present. H2 antihistamines may also be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid chilling of fish immediately after catch is an effective measure to prevent the accumulation of histamine, which can occur at ambient or high temperatures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/27\">",
"     27",
"    </a>",
"    ]. However, fish can become contaminated with scombroid on fishing boats, far from the consumer. Many experts have noted that much of the scombroid contaminated fish entering in the United States comes from off the coast of Central America, where it may be caught on long lines and improperly refrigerated at sea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) has instituted a mandatory Hazard Analysis and Critical Control Point system, under which all United States fish processors and importers must identify the points at which fish contamination may occur and must come up with a plan to prevent contamination. The FDA and United States Customs Service also inspect thousands of seafood shipments annually in an attempt to protect consumers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/29\">",
"     29",
"    </a>",
"    ]. Private companies offer chemical assays that test fish for histamine levels within an hour [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PARALYTIC SHELLFISH POISONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paralytic shellfish poisoning (PSP) is traditionally considered to be linked to algal blooms called \"red tides,\" even though it can occur in the absence of red tides. PSP primarily occurs in temperate climates, although it has been described in shellfish from tropical waters [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/35\">",
"     35",
"    </a>",
"    ]. In the United States, PSP primarily occurs along the northeast and northwest coasts.",
"   </p>",
"   <p>",
"    From 2010 to 2011, there was a marked increase in the number of PSP cases in southeast Alaska, all of which stemmed from the ingestion of non-commercially harvested shellfish (specifically, cockles, blue mussels,",
"    <span class=\"nowrap\">",
"     butter/little",
"    </span>",
"    neck clams, and Dungeness crabs) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/36\">",
"     36",
"    </a>",
"    ]. A subsequent CDC report noted that non-commercially-harvested Alaskan shellfish can have high levels of PSP toxin at any time of year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/36\">",
"     36",
"    </a>",
"    ]. Clinicians were urged to report suspected cases to health officials and to collect and freeze patient urine and shellfish samples (if available) for testing. In contrast, commercial shellfish are routinely monitored for PSP toxin in Alaska and are safe to consume [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The toxins that cause PSP are formed by dinoflagellates of the genus Alexandrium [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/38\">",
"     38",
"    </a>",
"    ]. These toxins, of which saxitoxin is the best known, are taken up by bivalve mollusks such as mussels, clams, scallops, and oysters, as well as by crabs and snails, with no apparent ill effect. In humans, however, the PSP toxins block sodium ion channels and rapidly cause neurologic symptoms ranging from perioral tingling, ataxia, difficulty swallowing, dizziness, paresthesias, weakness to paralysis, brainstem dysfunction, and respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/36,38\">",
"     36,38",
"    </a>",
"    ]. The case fatality rate is as high as 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/12\">",
"     12",
"    </a>",
"    ], and death may occur within 2 to 12 hours without ventilatory support. Patients who survive tend to improve gradually after 12 hours and are asymptomatic within a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is primarily supportive, and mechanical ventilation is important for severely affected patients.",
"   </p>",
"   <p>",
"    The PSP toxins are not destroyed by heat, marinating, or freezing. They do not cause shellfish to smell, taste, or appear abnormal. Prevention is dependent upon close monitoring of shellfish beds by health authorities and avoidance of closed areas (shellfish beds that the authorities have closed to harvesting).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NEUROTOXIC SHELLFISH POISONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurotoxic shellfish poisoning (NSP) is also associated with \"red tides.\" Unlike PSP, however, NSP tends to occur along the southeastern coast of the United States and in addition, the Gulf of Mexico, the Caribbean, and New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between 1998 and 2002, there were two outbreaks reported to the CDC in the United States that affected four persons, none of whom died [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NSP-related toxins are formed by the dinoflagellate species Gymnodidium breve, which produces both hemolytic toxins and neurotoxins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/38\">",
"     38",
"    </a>",
"    ]. These toxins, called brevetoxins, are taken up by shellfish and are also aerosolized during algal blooms. Brevetoxins increase sodium ion channel permeability. They also inhibit cathepsins, lysosomal proteinases that are found in phagocytes such as macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brevetoxins and their metabolites have been associated with two clinical syndromes. One syndrome occurs after eating contaminated shellfish and consists of gastrointestinal distress and neurologic symptoms such as paresthesias of the face, mouth, and extremities, dizziness, ataxia, and muscle aches. Patients may also experience",
"    <span class=\"nowrap\">",
"     hot/cold",
"    </span>",
"    temperature reversal, and seizures have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other syndrome, aerosolized red tide respiratory irritation (ARTRI), occurs when the toxins are inhaled from sea spray [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/38\">",
"     38",
"    </a>",
"    ]. ARTRI consists of nasal and respiratory irritation, rhinorrhea, and bronchoconstriction. People with chronic lung disease and asthma are especially susceptible.",
"   </p>",
"   <p>",
"    Treatment of both syndromes is supportive. Fluid replacement and intestinal decontamination with charcoal are important in NSP. Bronchodilators are useful for treatment and possibly also for prevention of ARTRI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NSP is generally not fatal in humans and most patients recover within 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/40\">",
"     40",
"    </a>",
"    ]. Brevetoxins do exact a heavy toll on marine and bird life, however, and have been responsible for large scale deaths of fish and manatees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIARRHEIC SHELLFISH POISONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrheic shellfish poisoning (DSP) occurs throughout the world. Major outbreaks, primarily associated with contaminated mussels, have occurred in Japan, Scandinavia, France, Spain, Chile, Uruguay, and Nova Scotia; no cases have been reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/13,41\">",
"     13,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several toxins have been associated with DSP, of which the best known is okadaic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/41\">",
"     41",
"    </a>",
"    ]. It is lipid soluble and acts as an inhibitor of certain types of phosphorylation in mammalian cells.",
"   </p>",
"   <p>",
"    A case definition of DSP would include chills and gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal cramps shortly after eating mollusks. The symptoms usually occur within two hours after shellfish consumption and resolve within two days. Treatment is supportive.",
"   </p>",
"   <p>",
"    Okadaic acid is mutagenic in Chinese hamster lung cells and has been found to promote skin tumors in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/41\">",
"     41",
"    </a>",
"    ]. The human health implications of this are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PUFFERFISH POISONING (TETRODOTOXIN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pufferfish poisoning is most commonly seen in Japan where the fish, called fugu, globefish, or blowfish, is considered a delicacy. Sporadic cases have been reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pufferfish poisoning is caused by tetrodotoxin, a neurotoxin produced by microorganisms associated with the fish [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/43\">",
"     43",
"    </a>",
"    ]. Tetrodotoxin is one of the deadliest natural toxins and is not destroyed by washing, cooking, or other food preparation. It concentrates in the liver and visceral organs along with the skin of the pufferfish and is also found in several species of frogs, salamanders, and octopus.",
"   </p>",
"   <p>",
"    Tetrodotoxin binds sodium channels, preventing sodium influx into nerve axons. It also acts on vascular smooth muscle and skeletal muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"     10",
"    </a>",
"    ]. Symptoms of tetrodotoxin occur rapidly after ingestion and include weakness, dizziness, paresthesias of the face and extremities, nausea, and loss of reflexes. With higher doses there is severe hypotension and, in some cases, general paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"     10",
"    </a>",
"    ]. Death can occur due to respiratory failure and hypotension. It is not unusual for the patient to remain conscious while paralyzed.",
"   </p>",
"   <p>",
"    Treatment of pufferfish poisoning consists of supportive care and intestinal decontamination with gut lavage and charcoal. Case reports suggest that anticholinesterases such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Saxitoxin, the cause of PSP, can also be found in pufferfish. Cases of neurologic symptoms, including numbness and tingling of the lips and mouth, have been reported to arise rapidly after the consumption of pufferfish caught in the area of Titusville, Florida [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/44\">",
"     44",
"    </a>",
"    ]. These symptoms generally resolve within hours to days, although one affected individual required intubation for 72 hours. Saxitoxin was confirmed by liquid chromatographic analysis. As a result of such cases, Florida banned the harvesting of pufferfish from certain bodies of water [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER MARINE TOXINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Amnesic shellfish poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnesic shellfish poisoning (ASP) was first recognized in 1987 following an outbreak involving 107 persons (four died) who became ill after consuming contaminated mussels cultivated off the coast of Prince Edward Island, Canada. It is caused by a heat stable toxin called domoic acid, which is produced by single-celled, algae-like organisms called diatoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Domoic acid is structurally related to glutamate and acts as a powerful excitatory neurotransmitter that can cause the death of neurons in the amygdala and hippocampus. It is taken up by shellfish and, after ingestion by humans, causes diarrhea and abdominal cramps, followed by headache, memory loss, and disorientation. In severe cases, domoic acid ingestion can lead to diminished reflexes, ophthalmoplegia, coma, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients who survive may have severe anterograde memory deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical therapy includes gut decontamination and supportive care. Benzodiazepines have been used to treat seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Possible estuary-associated syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible estuary-associated syndrome (PEAS) is believed to be a neurotoxin-mediated illness associated with exposure to waterways inhabited by dinoflagellates such as Pfiesteria. Pfiesteria has been found in the Tar-Pamlico and Neuse River estuaries of North Carolina and in the Pocomoke River on Maryland's Eastern Shore [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/40\">",
"     40",
"    </a>",
"    ]. Pfiesteria is associated with ulcerative lesions on fish and fish kills.",
"   </p>",
"   <p>",
"    Human laboratory workers and fishermen with PEAS have experienced respiratory and eye irritation, rashes, abdominal cramps and vomiting, and cognition and personality changes. Most of the neurocognitive symptoms appear to resolve within several months after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/48\">",
"     48",
"    </a>",
"    ]. Ongoing studies are investigating long-term effects of PEAS and Pfiesteria exposure. Visual contrast sensitivity, a test of patter-detection ability, is often markedly reduced in patients with acute and chronic PEAS, and may improve with treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19096/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hundreds of other marine toxins exist. In all cases, it is important for the clinician to work closely with local public health authorities. Clinicians should also remember that while marine toxin-induced diseases are not uncommon, food poisoning from infectious agents is far more prevalent and should always be included in the differential diagnosis of a patient with seafood-related illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29992029\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ciguatera poisoning accounts for more than half of the fish-related foodborne disease outbreaks in the United States and is the most common fish food poisoning in tropical coastal regions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ciguatera'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ciguatera poisoning can lead to gastrointestinal symptoms (eg, vomiting, diarrhea and cramping) and characteristic neurologic symptoms (paresthesias, blurred vision, and",
"      <span class=\"nowrap\">",
"       hot/cold",
"      </span>",
"      temperature reversal). Cardiovascular signs include bradycardia, heart block, and hypotension. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ciguatera poisoning is made by history and examination; there are no diagnostic assays. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of ciguatera poisoning is supportive. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scombroid fish poisoning is the most common seafood-associated disease in the United States and is also common throughout the world. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs and symptoms of scombroid toxicity usually begin within an hour of eating contaminated fish. Symptoms and signs, which include flushing, an erythematous rash, palpitations, and tachycardia, may be misdiagnosed as an allergic reaction. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scombroid poisoning usually responds rapidly to H1 antihistamines. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paralytic shellfish poisoning primarily occurs in temperate climates and is associated with a toxin that is taken up by mussels, clams, scallops, and oysters. In humans, however, these toxins block sodium ion channels and rapidly cause neurologic symptoms ranging from perioral tingling to coordination problems, brainstem dysfunction, paralysis, and respiratory failure. Treatment is supportive. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Paralytic shellfish poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurotoxic shellfish poisoning can lead to two different clinical syndromes. One syndrome occurs after eating contaminated shellfish and consists of gastrointestinal distress and neurologic symptoms, such as paresthesias of the face, mouth, and extremities. The other syndrome occurs when the toxins are inhaled from sea spray leading to respiratory irritation, rhinorrhea, and bronchoconstriction. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Neurotoxic shellfish poisoning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/1\">",
"      Lange WR. Ciguatera toxicity. Am Fam Physician 1987; 35:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/2\">",
"      Steinfeld AD, Steinfeld HJ. Ciguatera and the voyage of Captain Bligh. JAMA 1974; 228:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/3\">",
"      Glaziou P, Legrand AM. The epidemiology of ciguatera fish poisoning. Toxicon 1994; 32:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/4\">",
"      Whittle K, Gallacher S. Marine toxins. Br Med Bull 2000; 56:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/5\">",
"      Holt RJ, Miro G, Del Valle A. An analysis of poison control center reports of ciguatera toxicity in Puerto Rico for one year. J Toxicol Clin Toxicol 1984; 22:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/6\">",
"      Lewis ND. Disease and development: ciguatera fish poisoning. Soc Sci Med 1986; 23:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Ciguatera fish poisoning--Texas, 1998, and South Carolina, 2004. MMWR Morb Mortal Wkly Rep 2006; 55:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/8\">",
"      DiNubile MJ, Hokama Y. The ciguatera poisoning syndrome from farm-raised salmon. Ann Intern Med 1995; 122:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/9\">",
"      Lehane L. Ciguatera update. Med J Aust 2000; 172:176.",
"     </a>",
"    </li>",
"    <li>",
"     Baden DG, Fleming LE, Bean JA. Marine Toxins. In: Handbook of Clinical Neurology, deWolff, FA (Eds), Elsevier Science B V, New York 1995. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/11\">",
"      Clark RF, Williams SR, Nordt SP, Manoguerra AS. A review of selected seafood poisonings. Undersea Hyperb Med 1999; 26:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/12\">",
"      Mines D, Stahmer S, Shepherd SM. Poisonings: food, fish, shellfish. Emerg Med Clin North Am 1997; 15:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/13\">",
"      Sobel J, Painter J. Illnesses caused by marine toxins. Clin Infect Dis 2005; 41:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/14\">",
"      Pearn J. Neurology of ciguatera. J Neurol Neurosurg Psychiatry 2001; 70:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/15\">",
"      Pearn JH. Chronic fatigue syndrome: chronic ciguatera poisoning as a differential diagnosis. Med J Aust 1997; 166:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/16\">",
"      Chan TY. Lengthy persistence of ciguatoxin in the body. Trans R Soc Trop Med Hyg 1998; 92:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/17\">",
"      Lipp EK, Rose JB. The role of seafood in foodborne diseases in the United States of America. Rev Sci Tech 1997; 16:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/18\">",
"      Matta J, Navas J, Milad M, et al. A pilot study for the detection of acute ciguatera intoxication in human blood. J Toxicol Clin Toxicol 2002; 40:49.",
"     </a>",
"    </li>",
"    <li>",
"     Granade, HR. Ciguatoxin. Bad bug book-Foodborne pathogenic microorganisms and natural toxins handbook, 2nd edition, Food and Drug Administration, 2012, p. 176 . file://www.fda.gov/downloads/Food/FoodSafety/FoodborneIllness/FoodborneIllnessFoodbornePathogensNaturalToxins/BadBugBook/UCM297627.pdf (Accessed on February 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/20\">",
"      Palafox NA, Jain LG, Pinano AZ, et al. Successful treatment of ciguatera fish poisoning with intravenous mannitol. JAMA 1988; 259:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/21\">",
"      Schnorf H, Taurarii M, Cundy T. Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy. Neurology 2002; 58:873.",
"     </a>",
"    </li>",
"    <li>",
"     Schrank, K, Professor and Chief, Division of Emergency Medicine, University of Miami School of Medicine, 2006, personal communication.",
"    </li>",
"    <li>",
"     Blythe DG, Hack E, Washington G. The medical management of seafood poisonings. In: Foodborne Disease Handbook: Seafood and Environmental Toxins, Hui YH, Gorham JR, Murrell KD, et al (Eds), Marcel Dekker Inc., New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/24\">",
"      Perez CM, Vasquez PA, Perret CF. Treatment of ciguatera poisoning with gabapentin. N Engl J Med 2001; 344:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/25\">",
"      Crump JA, McLay CL, Chambers ST. Ciguatera fish poisoning. Postgrad Med J 1999; 75:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/26\">",
"      Fleming LE, Washington G. Scombroid fish poisoning. Shoreland's Travel Medicine Monthly 1998; 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Scombroid fish poisoning associated with tuna steaks--Louisiana and Tennessee, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/28\">",
"      Wallace BJ, Guzewich JJ, Cambridge M, et al. Seafood-associated disease outbreaks in New York, 1980-1994. Am J Prev Med 1999; 17:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/29\">",
"      New system for seafood safety. Environ Health Perspect 1998; 106:A475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/30\">",
"      Becker K, Southwick K, Reardon J, et al. Histamine poisoning associated with eating tuna burgers. JAMA 2001; 285:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/31\">",
"      Predy G, Honish L, Hohn W, Jones S. Was it something she ate? Case report and discussion of scombroid poisoning. CMAJ 2003; 168:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/32\">",
"      Ferran M, Y&eacute;benes M. Flushing associated with scombroid fish poisoning. Dermatol Online J 2006; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/33\">",
"      B&eacute;dry R, Gabinski C, Paty MC. Diagnosis of scombroid poisoning by measurement of plasma histamine. N Engl J Med 2000; 342:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/34\">",
"      Blakesley ML. Scombroid poisoning: prompt resolution of symptoms with cimetidine. Ann Emerg Med 1983; 12:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/35\">",
"      Hartigan-Go K, Bateman DN. Redtide in the Philippines. Hum Exp Toxicol 1994; 13:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Paralytic shellfish poisoning --- southeast Alaska, May--June 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1554.",
"     </a>",
"    </li>",
"    <li>",
"     State of Alaska Epidemiology Bulletin. Paralytic Shellfish Poisoning in Juneau, Kodiak, and Haines, June 2010. file://www.epi.alaska.gov/bulletins/docs/b2010 (Accessed on December 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/38\">",
"      Fleming L, Stinn J. Shellfish poisonings. Shoreland's Travel Medicine Monthly 1999; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/39\">",
"      Poli MA, Musser SM, Dickey RW, et al. Neurotoxic shellfish poisoning and brevetoxin metabolites: a case study from Florida. Toxicon 2000; 38:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/40\">",
"      Morris JG Jr. Pfiesteria, \"the cell from hell,\" and other toxic algal nightmares. Clin Infect Dis 1999; 28:1191.",
"     </a>",
"    </li>",
"    <li>",
"     Aune T, Yndestad M. Diarrhetic shellfish poisoning. In: Algal Toxins in Seafood and Drinking Water, Falconer IR (Ed), Academic Press Ltd., 1993. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/42\">",
"      Centers for Disease Control and Prevention (CDC). Tetrodotoxin poisoning associated with eating puffer fish transported from Japan--California, 1996. MMWR Morb Mortal Wkly Rep 1996; 45:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/43\">",
"      Watters MR. Organic neurotoxins in seafoods. Clin Neurol Neurosurg 1995; 97:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/44\">",
"      Centers for Disease Control and Prevention (CDC). Neurologic illness associated with eating Florida pufferfish, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:321.",
"     </a>",
"    </li>",
"    <li>",
"     www.floridamarine.org/features/view_article.asp?id=18918 (Accessed on May 23, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/46\">",
"      Perl TM, B&eacute;dard L, Kosatsky T, et al. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 1990; 322:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/47\">",
"      Teitelbaum JS, Zatorre RJ, Carpenter S, et al. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 1990; 322:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/48\">",
"      Grattan LM, Oldach D, Perl TM, et al. Learning and memory difficulties after environmental exposure to waterways containing toxin-producing Pfiesteria or Pfiesteria-like dinoflagellates. Lancet 1998; 352:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19096/abstract/49\">",
"      Shoemaker RC, Hudnell HK. Possible estuary-associated syndrome: symptoms, vision, and treatment. Environ Health Perspect 2001; 109:539.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2745 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19096=[""].join("\n");
var outline_f18_41_19096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29992029\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CIGUATERA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SCOMBROID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PARALYTIC SHELLFISH POISONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NEUROTOXIC SHELLFISH POISONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIARRHEIC SHELLFISH POISONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PUFFERFISH POISONING (TETRODOTOXIN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER MARINE TOXINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Amnesic shellfish poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Possible estuary-associated syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29992029\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/2745\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/2745|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/61/24540\" title=\"table 1\">",
"      Marine toxins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42408?source=related_link\">",
"      Marine envenomations from corals, sea urchins, fish, or stingrays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16346?source=related_link\">",
"      Seafood allergies: Fish and shellfish",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_41_19097="Ventricular pacing with 100 percent capture";
var content_f18_41_19097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1056px;\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Ventricular pacing with 100 percent capture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 186px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Every QRS complex is preceded by a pacemaker stimulus (marked by red lines). The QRS complex is abnormal, wide, and bizarre, resembling a ventricular beat. The QRS complexes usually have a left bundle branch block configuration since the ventricular lead is most commonly located in the right ventricle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19097=[""].join("\n");
var outline_f18_41_19097=null;
var title_f18_41_19098="Salicylate poisoning in children and adolescents";
var content_f18_41_19098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Salicylate poisoning in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19098/contributors\">",
"     A Karl Barnett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19098/contributors\">",
"     Edward W Boyer, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19098/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19098/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19098/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/41/19098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/41/19098/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/41/19098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (acetylsalicylic acid, ASA) in children has declined since it was associated with Reye syndrome. The incidence of unintentional salicylate intoxication among toddlers also has declined with limitation of the dose of aspirin in chewable, flavored tablets (to 81 mg), restriction of the number of tablets per bottle (to 36), and child-resistant packaging [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Most pediatric cases of severe salicylate poisoning or death occur among adolescents with intentional ingestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other salicylates, such as salicylic acid,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/14/30948?source=see_link\">",
"     bismuth",
"    </a>",
"    subsalicylate, and methyl salicylate, can cause intoxication when ingested or absorbed through the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Salicylic acid is a topical keratolytic agent and wart remover. Bismuth salicylate is a common ingredient in over-the-counter antidiarrheal agents (eg, Pepto-Bismol&reg;, Kaopectate&reg;). Magnesium subsalicylate in combination with caffeine, a combination product known as Diurex, is used as an &ldquo;antibloat&rdquo; medicine, but has been reported to cause salicylate toxicity in overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/6\">",
"     6",
"    </a>",
"    ]. Methyl salicylate (oil of wintergreen) is a common ingredient of Chinese herbal medications as well as liniments and ointments used in the management of musculoskeletal pain; it also is used as a flavoring agent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. One teaspoon (5 mL) of oil of wintergreen contains approximately 7 g of salicylate, the equivalent of 22 adult",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    tablets; ingestion of just 4 mL can be fatal in a child [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/8\">",
"     8",
"    </a>",
"    ]. The methyl salicylate concentration and the bioavailability of salicylate in methyl salicylate creams vary by preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and management of all salicylate intoxications are similar. An overview of salicylate intoxication in children and adolescents will be presented here. General issues relating to the clinical management of drug intoxication are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of pediatric exposures to salicylates reported to the American Association of Poison Control Centers Toxic Exposure Surveillance System (AAPCC TESS) has declined in the last two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/3\">",
"     3",
"    </a>",
"    ]. Among children there are approximately 20,000 salicylate exposures reported to United States regional poison control centers annually [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/11\">",
"     11",
"    </a>",
"    ]. Deaths from exploratory salicylate overdose in children are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS AND TOXICOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After ingestion, salicylate is rapidly absorbed from the GI tract, primarily from the jejunum and to a lesser extent, from the stomach and duodenum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The type of formulation (eg, liquid, effervescent, extended-release, enteric-coated) affects the degree of absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With therapeutic dosing of regular",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    tablets, peak plasma concentrations are usually achieved 15 to 60 minutes after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/17\">",
"     17",
"    </a>",
"    ]. Peak concentrations in overdose may be delayed as a result of pylorospasm or bezoar formation. Peak concentrations following ingestion of extended-release or enteric-coated preparations typically occur between 4 and 14 hours after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In therapeutic dosing, 80 to 90 percent of salicylate is protein-bound (primarily to albumin), and remains in the vascular space. However, in overdose, saturation of protein-binding sites leads to an increase in the free fraction of salicylate in the plasma, and increased drug reaching the tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salicylate is metabolized via several routes in the liver. In therapeutic dosing, the metabolism of salicylate, which involves glucuronidation, oxidation, and glycine conjugation, is described by first-order kinetics (where the rate is proportional to the dose) with a half-life of 15 to 20 minutes. At increasing doses, salicylate saturates these enzyme systems, and elimination of the drug undergoes a transition to zero-order kinetics (where a fixed amount of drug is metabolized per unit of time [Michaelis-Menten kinetics]) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, at increased doses, the half-life of salicylate is greatly increased and may be up to 30 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, with increasing doses, a greater-than-expected increase in serum and tissue concentration occurs; for children on chronic therapy, even a slight change in dose may result in a great increase in plasma concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salicylic acid (HS) is a weak acid that exists in a charged (deprotonated, sal-) and uncharged (protonated, H+) form:",
"   </p>",
"   <p>",
"    &nbsp;H+ &nbsp; + &nbsp; sal- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp; HS",
"   </p>",
"   <p>",
"    Uncharged molecules (HS), unlike charged molecules (sal-), can move easily across cellular barriers, including the blood-brain barrier and the epithelium of the renal tubule. Metabolic acidosis drives the above reaction to the right and increases the plasma concentration of HS, thereby promoting diffusion across the blood-brain barrier into the CNS. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of salicylate intoxication is directed toward increasing systemic pH via the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . By driving the above reaction to the left, salicylate anions are \"trapped\" in the blood. Alkalinization also \"traps\" salicylate anions within the renal tubule, preventing back-diffusion across the renal epithelium into the systemic circulation.",
"   </p>",
"   <p>",
"    An alkaline environment protects the patient from detrimental tissue toxicity, especially in the central nervous system. To appreciate how alkalinization acts, it is important to note that salicylic acid is a weak acid with a pKa of 3.0. Thus, the Henderson-Hasselbalch equation for the reaction above can be expressed as:",
"   </p>",
"   <p>",
"    pH &nbsp; = &nbsp; 3.0 &nbsp; + &nbsp;log [sal -]",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    [HS]",
"   </p>",
"   <p>",
"    At the normal extracellular pH of 7.40, the ratio of deprotonated (charged) salicylic acid to protonated (uncharged) salicylate is about 1:25,000; that is, only 0.004 percent of the total extracellular salicylate exists in deprotonated form. Salicylic acid is nonpolar, lipid-soluble, and able to cross cell membranes; deprotonated salicylate is polar and crosses membranes poorly. As a result, the plasma and central nervous system (CNS) salicylic acid concentrations are in diffusion equilibrium, but not the ionized salicylate concentrations.",
"   </p>",
"   <p>",
"    If the systemic pH is increased, plasma salicylic acid concentration will fall and cause diffusion of salicylic acid out of the CNS and other tissues into the extracellular fluid down a favorable concentration gradient where it will be trapped as ionized salicylate. The fall in the CNS salicylic acid concentration then causes the first equation to move to the right in the brain cell. This increase in the cellular HS concentration promotes further drug movement out of the CNS.",
"   </p>",
"   <p>",
"    Increasing the arterial pH from 7.20 to 7.50 will decrease the fractional concentration of HS from 0.006 to 0.003 percent. Although this change appears trivial, it will promote a significant reduction in the tissue salicylate concentration. This will be accompanied by an initial increment in the plasma salicylate concentration, but it is the tissue levels that are dangerous to the patient.",
"   </p>",
"   <p>",
"    Concurrent alkalinization of the urine is also beneficial by increasing salicylate excretion. Since the salicylate anion is highly protein-bound, it enters the urine primarily via secretion by the organic anion secretory pathway in the proximal tubule, rather than by glomerular filtration. Alkalinization of the urine converts urinary salicylic acid to ionized salicylate thereby minimizing the back-diffusion of secreted salicylic acid out of the tubular lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/20\">",
"     20",
"    </a>",
"    ]. As an example, raising the urine pH from 6.5 to 8.1 by the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    can increase total salicylate excretion more than fivefold [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Maintaining a high-urine flow rate with hydration further enhances this process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylate has multiple cellular and systemic effects that define its clinical presentation in overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/3,23,24\">",
"     3,23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of the respiratory center of the medulla results in increased respiratory rate, respiratory alkalosis, increased renal elimination of HCO3, and increased insensible fluid loss.",
"     </li>",
"     <li>",
"      Interference with cellular metabolism (uncoupling of oxidative phosphorylation) leads to metabolic acidosis, hyperpyrexia, fluid loss, and hypoglycemia.",
"     </li>",
"     <li>",
"      Inhibition of the tricarboxylic acid cycle leads to metabolic acidosis.",
"     </li>",
"     <li>",
"      Inhibition of cyclooxygenase results in decreased synthesis of prostaglandins, prostacyclin, and thromboxanes.",
"     </li>",
"     <li>",
"      Stimulation of the chemoreceptor trigger zone in the medulla causes nausea and vomiting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmarks of acute salicylate overdose are hyperpnea, tachypnea, metabolic acidosis, and to a lesser extent, tachycardia. Early symptoms include tinnitus, fever, vertigo, nausea, vomiting, and diarrhea; more severe intoxication can cause altered mental status, coma, noncardiogenic pulmonary edema, and death. Salicylate toxicity is associated with several clinical and laboratory findings (",
"    <a class=\"graphic graphic_table graphicRef74079 \" href=\"UTD.htm?3/32/3597\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Salicylate intoxication, known as salicylism, may be acute, chronic, or acute-on-chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/25\">",
"     25",
"    </a>",
"    ]. Chronic and acute-on-chronic toxicity are uncommon in children, since",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    is rarely used on a daily basis in children. The discussion below will focus on acute salicylate toxicity. However, it should be noted that chronic or therapeutic (repeated dose) salicylate poisonings in children usually are more serious and involve more severe clinical manifestations than acute ingestions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of salicylate ingestion are dependent, to some extent, upon the ingested dose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/3\">",
"     3",
"    </a>",
"    ]. As a general rule, ingestions of less than 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    are associated with mild symptoms, ingestions of 300 to 500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    are associated with moderate toxicity, and ingestions of &gt;500 mg are associated with death. Fatal salicylate intoxication can occur after the ingestion of 10 to 30 g by adults and as little as 3 g by children. Death typically results from severe CNS toxicity with complete loss of function of the cardiorespiratory centers.",
"   </p>",
"   <p>",
"    Although there is no absolute correlation between the plasma salicylate concentration and symptoms, most patients show signs of intoxication when the plasma concentration exceeds 30 to 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (300 to 500",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    2.2 to 3.6",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    the usual therapeutic range is 10 to 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100 to 200",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    0.7 to 1.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician should take care in reading and interpreting laboratory reports since some laboratories report salicylate levels as",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    rather than",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    such values will be 10-fold higher than those discussed in this topic review. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Evaluation and diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Salicylate poisoning leads to a variety of clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vital signs",
"      </strong>",
"      &ndash; Salicylate intoxication can lead to increased respiratory rate, temperature, and heart rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Salicylates stimulate the medullary respiratory center, causing tachypnea and hyperventilation. The respiratory rate must be carefully monitored in all patients with suspected salicylate overdose. Salicylate-intoxicated patients have a dramatic increase in minute ventilation. The rate and depth of breathing provide critical clues to salicylate toxicity.",
"     </li>",
"     <li>",
"      Salicylates uncouple oxidative phosphorylation in the mitochondria; this generates heat and may increase body temperature. A lack of hyperthermia, however, should not be used to exclude the diagnosis of salicylate toxicity. Hypovolemia further limits the ability to dissipate heat. Children are able to tolerate hyperpyrexia somewhat better than adults, in whom hyperpyrexia suggests a grave prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salicylate ingestion can cause tachycardia due to hypovolemia, agitation, or general distress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tinnitus",
"      </strong>",
"      &ndash; Salicylates commonly cause tinnitus, and may do so at levels within the therapeutic range (20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.5",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"      This specific symptom should be sought in all patients with potential salicylate toxicity. As CNS salicylate concentration increases, diminished auditory acuity may ensue, sometimes leading to deafness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Nausea and vomiting",
"      </strong>",
"      &ndash; Salicylate can cause nausea and vomiting through multiple mechanisms. These include direct stimulation of the chemoreceptor trigger zone in the medulla, delayed gastric emptying, direct irritation of the gastric mucosa, and decreased production of prostaglandins (leading to deterioration of the protective mucosal barrier).",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary edema",
"      </strong>",
"      &ndash; Salicylate-induced noncardiogenic pulmonary edema is more common among older patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/29\">",
"       29",
"      </a>",
"      ], but does occur in children [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/30\">",
"       30",
"      </a>",
"      ]. In one five-year retrospective review of 20 cases of pediatric salicylate poisoning, two children developed pulmonary edema; both children died, while there were no deaths among the 18 without pulmonary edema [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/30\">",
"       30",
"      </a>",
"      ]. Pulmonary edema may occur in the setting of falling or near-therapeutic plasma salicylate concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link&amp;anchor=H16#H16\">",
"       \"Noncardiogenic pulmonary edema\", section on 'Salicylate toxicity'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Hypoxia is the major clinical manifestation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/25\">",
"       25",
"      </a>",
"      ], although crackles may be present. In addition, arterial blood gas analysis may demonstrate a widened arterial-alveolar gradient [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/30\">",
"       30",
"      </a>",
"      ]. A chest radiograph should be obtained in children with salicylism in whom pulmonary edema is suspected. Radiographic signs of pulmonary edema, which may or may not be present, include pleural effusion, interstitial edema, fluid in the fissures, and septal lymphatic distension.",
"      <br/>",
"      <br/>",
"      Salicylate-induced pulmonary edema can complicate volume resuscitation and the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      , two mainstays of treatment. Thus, pulmonary edema is an absolute indication for hemodialysis (see",
"      <a class=\"local\" href=\"#H33\">",
"       'Hemodialysis'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <strong>",
"       Central nervous system abnormalities",
"      </strong>",
"      &ndash; CNS toxicity, suggestive of severe poisoning, may occur in the setting of falling or near-therapeutic plasma salicylate concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/31\">",
"       31",
"      </a>",
"      ]. The development of acidemia increases the risk of CNS toxicity since salicylate, a neutral compound at acidic pH, is able to cross the blood-brain barrier and enter the CNS (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacokinetics and toxicokinetics'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      CNS toxicity is more common among children younger than five years of age than among older children and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/27,32\">",
"       27,32",
"      </a>",
"      ]. CNS toxicity manifests as agitation, confusion, restlessness, seizures, and rarely, coma. Seizures are a more common presentation among children with chronic ingestions and severe metabolic acidosis than among children with acute ingestions [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/27\">",
"       27",
"      </a>",
"      ]. The development of CNS toxicity is an indication for hemodialysis, regardless of the plasma salicylate concentration (see",
"      <a class=\"local\" href=\"#H33\">",
"       'Hemodialysis'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <strong>",
"       Acid-base derangement",
"      </strong>",
"      &ndash; A variety of acid-base disturbances can occur with salicylate intoxication. The typical abnormality is a primary respiratory alkalosis with a primary metabolic acidosis. Salicylates stimulate the respiratory center directly, leading to hyperpnea. This results in a decreased PCO2 and respiratory alkalosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/23,32,33\">",
"       23,32,33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"       \"Simple and mixed acid-base disorders\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The increase in respiratory rate is critical to survival since alkalosis prevents CNS toxicity, which is the major cause of death. The respiratory alkalosis, which normally promotes lactic acid production to minimize the rise in pH, appears to play a contributory role in the development of metabolic acidosis. In experimental animals, lactate accumulation is minimal if the initial fall in PCO2 is prevented, but gradually becomes more prominent as hypocapnia is permitted to occur [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/34\">",
"       34",
"      </a>",
"      ]. Salicylic acid itself (mol wt 180) has only a minor effect on serum pH, since a plasma level of 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      represents a concentration that is less than 3",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"      Thus, the metabolic acidosis following salicylate poisoning is due primarily to the accumulation of organic acids, including lactic acid and ketoacids [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/33-36\">",
"       33-36",
"      </a>",
"      ]. Inhibition of the tricarboxylic acid cycle by salicylates also contributes to the development of metabolic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link\">",
"       \"Approach to the child with metabolic acidosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Metabolic acidosis increases the concentration of uncharged salicylic acid, thereby promoting diffusion across the blood-brain barrier into the central nervous system. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacokinetics and toxicokinetics'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The net effect of these changes in most adults is respiratory alkalosis or a mixed respiratory alkalosis-metabolic acidosis. Pure metabolic acidosis is unusual in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/33\">",
"       33",
"      </a>",
"      ], but is more common in children [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/32\">",
"       32",
"      </a>",
"      ]. Children with mild to moderate acute salicylate poisoning lose the respiratory drive and are more likely to present with mixed metabolic and respiratory acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/24,32\">",
"       24,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"       \"Simple and mixed acid-base disorders\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Acute respiratory acidosis may also occur in adolescents and adults who ingest respiratory depressants at the same time as salicylate [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/33\">",
"       33",
"      </a>",
"      ]. Ingestion of respiratory depressants decreases the respiratory drive, leading to increased PaCO2 and decreased plasma pH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"       \"Simple and mixed acid-base disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fluids, electrolytes, and glucose",
"      </strong>",
"      &ndash; Fluid and electrolyte abnormalities are common in salicylate poisoning. Insensible fluid losses from hyperpyrexia, vomiting, diaphoresis, and an elevated metabolic rate can cause hypovolemia. In severe intoxication, free water losses may reach 4 to 6",
"      <span class=\"nowrap\">",
"       L/m2",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/13,24\">",
"       13,24",
"      </a>",
"      ], resulting in hypernatremia.",
"      <br/>",
"      <br/>",
"      During the early stages of salicylate intoxication, when respiratory alkalosis is the primary acid-base disturbance, there is increased loss of HCO3-, and the kidneys attempt to conserve H+ over K+. As poisoning progresses and potassium is depleted, the kidneys attempt to conserve K+, producing a paradoxically acidic urine [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/24\">",
"       24",
"      </a>",
"      ]. Hypokalemia, if present, must be treated aggressively. (See",
"      <a class=\"local\" href=\"#H15449147\">",
"       'Potassium repletion'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Early in the course, the patient may have hyperglycemia from glycogenolysis, stimulation of gluconeogenesis, and decreased peripheral utilization of glucose. At this stage, urine ketones may be positive [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/25\">",
"       25",
"      </a>",
"      ]. As glucose stores are depleted, hypoglycemia may ensue from impaired gluconeogenesis and increased utilization [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/4,39,40\">",
"       4,39,40",
"      </a>",
"      ]. In addition, salicylate intoxication may decrease CNS glucose levels despite a normal peripheral glucose level if CNS glucose utilization exceeds blood supply [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link\">",
"       \"Etiology of hypoglycemia in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hematologic",
"      </strong>",
"      &ndash; Hematologic abnormalities associated with salicylate intoxication include leukocytosis, inhibition of platelet function, and disturbances in vitamin K-dependent and vitamin K-independent clotting factors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/42-44\">",
"       42-44",
"      </a>",
"      ]. These abnormalities may manifest with bruising or bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylism should be suspected in patients with hyperventilation, tachypnea, tachycardia, diaphoresis, tinnitus, and increased anion gap metabolic acidosis. The diagnosis is confirmed by measurement of the plasma salicylate concentration, which should be obtained in patients with these findings, even if a history of salicylate ingestion is lacking. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Plasma salicylate'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the child or adolescent with salicylate intoxication should include as much detail about the ingestion as possible.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How much salicylate was ingested (including the dose per tablet and number of tablets per container)?",
"     </li>",
"     <li>",
"      Was the child or adolescent taking salicylate on a regular basis (including over-the-counter antidiarrheal preparations eg, Pepto-Bismol&reg;, the US preparation of Kaopectate&reg;, or Diurex&reg;)?",
"     </li>",
"     <li>",
"      Was the ingestion intentional?",
"     </li>",
"     <li>",
"      Does the child or adolescent have any underlying medical problems or take any medication on a regular basis?",
"     </li>",
"     <li>",
"      Does the child or adolescent have symptoms (eg, fever, tinnitus, nausea, vomiting, respiratory difficulty, agitation, confusion, restlessness)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include a complete set of vital signs and evaluation for diaphoresis, hyperpnea (increase depth of respiration), CNS disturbance, tinnitus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hearing loss. The lungs should be carefully examined for signs of pulmonary edema (eg, hypoxemia, crackles), which may complicate therapy and is an indication for hemodialysis. Vital signs should be frequently remeasured. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of the child or adolescent with salicylate intoxication should include plasma salicylate concentration and additional tests that help to assess the severity of the ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Plasma salicylate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma salicylate concentration should be measured in all patients in whom salicylate intoxication is suspected. The result should be interpreted in conjunction with the clinical findings, particularly the plasma pH. Acidosis, by promoting the diffusion of salicylic acid into the CNS, increases the severity of toxicity.",
"   </p>",
"   <p>",
"    Plasma salicylate concentrations should be repeated several hours after presentation because of the possibility of prolonged or delayed absorption. A decreasing plasma concentration in a patient with progressive clinical manifestations of salicylism may indicate increased tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CNS distribution. In patients with documented salicylate intoxication, plasma salicylate concentrations should be remeasured frequently (eg, every two to four hours) until there is a consistent decrease in the concentration and clinical improvement in the patient.",
"   </p>",
"   <p>",
"    The clinician should take care in reading and interpreting laboratory reports since some laboratories report salicylate levels as",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    rather than",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    such values will be tenfold higher than those discussed in this topic review. Thus, a laboratory report of \"a salicylate level of 110\" in an asymptomatic individual should prompt the clinician to check the units of the result in order to avoid confusion.",
"   </p>",
"   <p>",
"    The usual therapeutic range is 10 to 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100 to 300",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    0.7 to 2.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/23\">",
"     23",
"    </a>",
"    ]. Although there is no absolute correlation between plasma salicylate concentration and symptoms, most patients show signs of intoxication when the plasma concentration exceeds 30 to 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (400 to 500",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    2.9 to 3.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Plasma salicylate concentrations &gt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;1000",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    &gt;7.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in acute intoxication and &gt;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;600",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    &gt;4.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in chronic intoxication are indications for hemodialysis. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Hemodialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Life-threatening complications of salicylate intoxication may occur when plasma concentrations are decreasing or near-therapeutic. Clinicians must continue to follow patients closely, even as salicylate concentrations decline. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The Done nomogram was developed to correlate plasma salicylate levels with toxicity for acute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    ingestions; however, it is no longer in clinical use. The Done nomogram fails to accurately predict toxicity based upon the plasma concentration alone; however, patients with higher levels generally are sicker than those with lower values [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/45\">",
"     45",
"    </a>",
"    ]. Mortality from salicylate poisoning is strongly correlated with CNS salicylate levels, but these are not routinely measured in clinical practice. Ultimately, plasma salicylate concentrations must be interpreted in conjunction with the clinical status of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following tests are important in evaluating the severity of salicylate intoxication",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the need for hemodialysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial blood gas",
"     </li>",
"     <li>",
"      Electrolytes and glucose",
"     </li>",
"     <li>",
"      Plasma creatinine (to evaluate for renal failure, which is an indication for hemodialysis) (see",
"      <a class=\"local\" href=\"#H33\">",
"       'Hemodialysis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Urinalysis (as poisoning progresses and potassium is depleted). The kidneys attempt to conserve K+, producing a paradoxically acidic urine; urine pH is also followed to monitor success of alkalinization (see",
"      <a class=\"local\" href=\"#H30\">",
"       'Urine alkalinization'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending upon the circumstances of the ingestion and the severity of symptoms, the following additional tests may be indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest radiograph, particularly in patients with hypoxemia or crackles, to evaluate for pulmonary edema",
"     </li>",
"     <li>",
"      Toxicology screen, particularly in intentional ingestions",
"     </li>",
"     <li>",
"      Plasma",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concentration (since many over-the-counter preparations contain both",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      and acetaminophen) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link\">",
"       \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Electrocardiogram (particularly in patients with hypokalemia)",
"     </li>",
"     <li>",
"      Complete blood count",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prothrombin time and partial thromboplastin times may be obtained in the initial evaluation of patients with unknown salicylate exposure who manifest fever and shock; although abnormal findings may be present (eg, leukocytosis, impaired clotting), these abnormalities may be seen in both salicylism or sepsis",
"     </li>",
"     <li>",
"      Pregnancy test",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of salicylate ingestion may or may not be known. In cases of occult exposure, the differential diagnosis of salicylism includes diabetic ketoacidosis (DKA), sepsis, pneumonia, iron intoxication, ethylene glycol ingestion, and ethanol intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with DKA may present with nausea, vomiting, abdominal pain, lethargy, hypovolemia, hyperglycemia, hyperosmolality, and metabolic acidosis. The diagnosis of uncontrolled diabetes mellitus is usually suspected from the clinical history (eg, polyphagia, polydipsia, polyuria) and on laboratory testing, the presence of hyperglycemia and a high-anion gap metabolic acidosis with ketonuria and ketonemia. In contrast to patients with DKA, patients with salicylism may be hypoglycemic. Plasma salicylate concentrations should be measured in patients in whom the distinction cannot be made clinically. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The findings of metabolic acidosis, tachypnea, hypoglycemia, hypovolemia, leukocytosis, and clotting abnormalities may mimic sepsis, pneumonia, or the systemic inflammatory response syndrome, particularly in patients with chronic salicylism or noncardiogenic pulmonary edema [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/44,47,48\">",
"       44,47,48",
"      </a>",
"      ]. Salicylate intoxication should be considered when a source of infection is not readily apparent, since survival in both of these disorders is dependent upon prompt recognition and management.",
"     </li>",
"     <li>",
"      Similar to acute salicylate intoxication, acute iron intoxication may be associated with metabolic acidosis, vomiting, leukocytosis, hemoconcentration, elevated transaminases, prolonged prothrombin time, and hyperglycemia. Plasma concentrations of iron and salicylate should be measured to make the diagnosis so that appropriate therapy can be instituted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2970?source=see_link\">",
"       \"Acute iron poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ethylene glycol intoxication is associated with neurologic abnormalities, tachypnea, pulmonary edema, and a metabolic acidosis with increased anion gap (oxalate is the unmeasured anion). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similar to salicylate intoxication, ethanol intoxication in children causes metabolic acidosis with increased anion gap, elevated lactate, hypoglycemia, and neurologic symptoms. Ethanol intoxication is diagnosed by measuring a blood alcohol concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link&amp;anchor=H28#H28\">",
"       \"Etiology of hypoglycemia in infants and children\", section on 'Ethanol'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview describes the treatment priorities for salicylate poisoning (",
"    <a class=\"graphic graphic_table graphicRef74079 \" href=\"UTD.htm?3/32/3597\">",
"     table 1",
"    </a>",
"    ). As with all poisoned patients, treatment consists of rapid assessment and stabilization of the airway, breathing, and circulation. This should be followed by gastrointestinal decontamination and the initiation of specific therapy.",
"   </p>",
"   <p>",
"    The goals of treatment of salicylate intoxication are to correct fluid and electrolyte imbalance and to enhance excretion. Treatment of salicylate intoxication is directed toward increasing systemic pH by the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . Alkalinization \"traps\" salicylate anions in the blood, since charged molecules do not easily diffuse across the blood-brain barrier into the CNS. Alkalinization also \"traps\" salicylate anions within the renal tubule, preventing back-diffusion across the renal epithelium into the systemic circulation. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pharmacokinetics and toxicokinetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children and adolescents with significant salicylate toxicity should be managed in consultation with the toxicology service or advice from a regional poison control center. In the United States, call 1-800-222-1222 or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ). In addition, it is advisable to consult with the nephrology service early in a patient's course, even in the absence of indications for acute hemodialysis. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Hemodialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15448972\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key aspects of supporting the child or adolescent with salicylate poisoning include maintaining oxygenation, ensuring adequate minute ventilation, providing intravenous glucose, and repletion of fluid and potassium losses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intubation of the salicylate-poisoned patient is dangerous and should be avoided, if possible. Salicylate acts on the respiratory center of the medulla to increase the respiratory rate and can produce a dramatic increase in minute ventilation. As noted above, the resulting respiratory alkalosis \"traps\" salicylate anions in the blood, preventing them from crossing into the CNS.",
"   </p>",
"   <p>",
"    When intubation is necessary due to obtundation, hypotension, hypoventilation, or severe metabolic acidosis, care must be taken to ensure appropriately high-minute ventilation and maintain alkalemia with serum pH 7.45 to 7.55. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Urine alkalinization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Importantly, mechanical ventilation is generally incapable of delivering such high-minute ventilation, and ventilator asynchrony may actually",
"    <strong>",
"     decrease",
"    </strong>",
"    the patient's ability to maintain appropriate acid-base homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/49\">",
"     49",
"    </a>",
"    ]. As minute ventilation falls following intubation, increased CO2 concentrations worsen acidosis. This, in turn, leads to redistribution of salicylate into peripheral tissues and, potentially, worsens toxicity. Patients who require intubation usually also require hemodialysis. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Hemodialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Intubation of tachypneic patients following a salicylate overdose out of concern that \"they may eventually tire\" has resulted in death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Thus, prophylactic intubation should be reserved for those patients with",
"    <strong>",
"     hypoventilation",
"    </strong>",
"    , as determined by clinical evaluation or blood gas analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen should be administered as needed. The presence of acute lung injury may lead to very high-oxygen requirements.",
"   </p>",
"   <p>",
"    Pulmonary edema, if present, should be treated initially with oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/3\">",
"     3",
"    </a>",
"    ]. If necessary, continuous positive airway pressure (CPAP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intubation may be tried. Intubation with positive end-expiratory pressure (PEEP) may be necessary, but should be avoided if possible. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Airway'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous fluids should be administered as necessary to replace insensible fluid losses from hyperpyrexia, vomiting, diaphoresis, and elevated metabolic rate. The administered fluid is typically 5 percent dextrose to which",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    and potassium have been added. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Urine alkalinization'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15449147\">",
"     'Potassium repletion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Intravenous fluids should be administered cautiously to avoid pulmonary edema, usually at a rate of 1.5 to 2.0 times maintenance. The rate should be adjusted as necessary to produce 1 to 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of urine per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15449105\">",
"    <span class=\"h3\">",
"     Supplemental glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylate intoxication may decrease CNS glucose levels despite a normal peripheral glucose level [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/41\">",
"     41",
"    </a>",
"    ]. Supplemental glucose should be given to patients with altered mental status regardless of serum glucose concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Glucose therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15449147\">",
"    <span class=\"h3\">",
"     Potassium repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia, if present, must be treated aggressively. Hypokalemia promotes the absorption of potassium in the distal tubule; this absorption occurs via a K+-H+ exchange pump. The secretion of protons interferes with efforts at urinary alkalinization, which is a mainstay of therapy. Intravenous potassium repletion should be provided based upon the degree of hypokalemia as reflected by the serum potassium. In most patients, the addition of 20 to 40",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/17/11542?source=see_link\">",
"     potassium chloride",
"    </a>",
"    to the recommended continuous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    infusion is sufficient. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Urine alkalinization'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=see_link&amp;anchor=H10#H10\">",
"     \"Chapter 11B: Regulation of renal hydrogen excretion\", section on 'Plasma potassium concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Gastrointestional decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that children and adolescents with an acute salicylate overdose receive gastrointestinal decontamination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC, 1",
"    <span class=\"nowrap\">",
"     g/kg;",
"    </span>",
"    maximum single dose: 50 grams). AC should be withheld in patients who have altered mental status and may not be able to protect their airway, unless endotracheal intubation is performed first. Because",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    is known to form gastric concretions in poisoned patients which may delay absorption and peak plasma salicylate levels as long as 60 hours after large ingestions, many experts suggest that AC be given to any patient with clinical signs of salicylate poisoning, even several hours after ingestion.",
"   </p>",
"   <p>",
"    Evidence for the benefit of AC in salicylate poisoned children is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       Activated charcoal",
"      </a>",
"      binds to salicylates [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/25,52\">",
"       25,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small trial in healthy adult volunteers who received AC 30 minutes after",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      ingestion found that peak salicylate levels were 50 percent lower than in untreated controls [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another small trial in healthy adult volunteers who received AC three hours after ingestion of enteric-coated",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      also showed a significant decrease in absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendation of AC administration following salicylate overdose also derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications. Because of adverse effects, such as vomiting and dehydration, the combination of a cathartic (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    ) and AC should be used sparingly, if at all, and only a single dose of a cathartic should be given to any patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H27#H27\">",
"     \"Decontamination of poisoned children\", section on 'Cathartics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H10032467#H10032467\">",
"     \"Decontamination of poisoned children\", section on 'Activated charcoal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993761#H18993761\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Activated charcoal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993978#H18993978\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Cathartics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend not performing gastric emptying by gastric lavage or by syrup of ipecac-induced emesis in patients who ingest salicylates. This recommendation is based upon randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15449335\">",
"    <span class=\"h2\">",
"     Elimination enhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary alkalinization and hemodialysis are the primary methods to enhance elimination of salicylates. Multiple dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    may also provide some benefit, primarily by preventing ongoing salicylate absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Urine alkalinization",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that children and adolescents with salicylate poisoning and clinical findings of toxicity receive urine alkalinization in addition to administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    and supportive care. The goal of this therapy is to achieve a urine pH &gt;7.5 while maintaining a serum pH no higher than 7.55. Once initial fluid resuscitation has occurred, this therapy is generally started by administering an IV bolus of 1-2",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    (1-2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 8.4 percent [1",
"    <span class=\"nowrap\">",
"     mEq/mL]",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ), followed by a continuous infusion of sodium bicarbonate at approximately 1.5-2 times maintenance requirements. The fluid for continuous infusion is mixed by placing 150 mEq of sodium bicarbonate into one liter of 5 percent dextrose in water. Patients with hypokalemia should have 20-40",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/17/11542?source=see_link\">",
"     potassium chloride",
"    </a>",
"    added to the infusate. Prior to the initiation of therapy, baseline measurements of electrolytes, blood urea nitrogen, serum creatinine, glucose, systemic pH, urinary pH, and serum drug concentrations should be performed. Placement of a Foley catheter is recommended to accurately measure urine output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link&amp;anchor=H10#H10\">",
"     \"Enhanced elimination of poisons\", section on 'Technique'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link&amp;anchor=H12#H12\">",
"     \"Enhanced elimination of poisons\", section on 'Children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    infusion rate should be titrated to maintain a urine pH &ge;7.5. Increases in serum pH up to 7.55 are well tolerated in patients with normal renal function. Subsequent fluid administration should be based upon urine output and ongoing losses. The sodium bicarbonate infusion should continue until clinical findings of toxicity have resolved and the plasma salicylate concentration is less than 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (300",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alkalemia from a respiratory alkalosis is",
"    <strong>",
"     not",
"    </strong>",
"    a contraindication to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy. It is common for salicylate-poisoned patients to present with an arterial pH between 7.50 and 7.55; these patients should be treated with sodium bicarbonate. Blood gas analysis every two hours is indicated for monitoring to prevent severe alkalemia (arterial pH &gt;7.55) which may be associated with high mortality from neurologic and cardiac complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This recommendation for urine alkalinization derives from the following evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 22 adults with moderate salicylate poisoning, the 6 patients who received urinary alkalinization had a significantly greater clearance of salicylates than the 16 patients who only received oral fluids (mean clearance 24 versus 1.4",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively). Patients who received alkalinization also had a significantly reduced half life of elimination for salicylates when compared to controls (mean half-life 9 versus 29 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In human volunteers, urinary alkalinization increases the amount of salicylic acid excreted in the urine unchanged from 2 to 31 percent and increases its clearance from 1 to 100",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/22,56\">",
"       22,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a report describing two separate episodes of severe salicylate poisoning (seizures with salicylate level &gt;69",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [690",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      5",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      in the same patient, urinary alkalinization alone was given for one episode and hemodialysis alone was performed for the other [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/57\">",
"       57",
"      </a>",
"      ]. When compared to hemodialysis alone, urinary alkalinization was more rapidly performed and resulted in a faster reduction in plasma salicylate concentration during the first four hours of care. Similar salicylate levels were achieved at 24 hours after overdose with both methods of elimination enhancement.",
"     </li>",
"     <li>",
"      An abrupt fall in blood pH in patients with salicylate poisoning has resulted in exacerbation of toxicity and death [",
"      <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/50\">",
"       50",
"      </a>",
"      ]. The mechanism of this sudden deterioration is thought to be related to increased salicylic acid uptake by the tissues, especially the central nervous system, as a result of the increased blood salicylic acid level. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacokinetics and toxicokinetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, urinary alkalinization enhances the excretion and significantly shortens the half-life of salicylates in poisoned patients. This therapy also produces an alkaline environment in the blood which mitigates tissue toxicity. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pharmacokinetics and toxicokinetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11478562\">",
"    <span class=\"h3\">",
"     Treatments to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forced diuresis should not be performed. It is less effective than urinary alkalinization in enhancing salicylate elimination and provides no added benefit when used in conjunction with alkalinization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/21,56\">",
"     21,56",
"    </a>",
"    ]. In addition, attempts at forced diuresis can cause fluid overload, increasing the risk of pulmonary or cerebral edema, and may make it more difficult to alkalinize the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/21,56\">",
"     21,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    also should not be administered since it produces alkaline urine by causing renal elimination of bicarbonate and a systemic metabolic acidosis that is harmful in patients with salicylate poisoning. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pharmacokinetics and toxicokinetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficiency of salicylate removal can be enhanced by hemodialysis. It is advisable to consult with the nephrology service early in the patient's course, even in the absence of specific indications for acute hemodialysis. This is because the clinical condition in children with salicylate poisoning can deteriorate rapidly, even if the plasma salicylate concentration is decreasing or near-therapeutic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend hemodialysis in addition to urine alkalinization and multiple dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    for patients with salicylate poisoning and any one of the following clinical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent CNS disturbance (eg, coma, seizures) or persistent focal neurologic signs",
"     </li>",
"     <li>",
"      Pulmonary or cerebral edema",
"     </li>",
"     <li>",
"      Renal insufficiency that interferes with salicylate excretion",
"     </li>",
"     <li>",
"      Intractable acidosis",
"     </li>",
"     <li>",
"      Clinical deterioration despite aggressive and appropriate supportive care (eg, worsening metabolic acidosis or the development of respiratory acidosis)",
"     </li>",
"     <li>",
"      Plasma salicylate concentration &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      7.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the setting of acute ingestion or plasma salicylate concentration &gt;60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      4.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the setting of chronic salicylate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A common error is for clinicians to not dialyze patients who meet one or more clinical criteria because the plasma salicylate concentration is not available or does not exceed the threshold values listed above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/25,51\">",
"     25,51",
"    </a>",
"    ]. However, fatal poisoning despite plasma salicylate levels below these thresholds has been reported. Thus, emergency clinicians and nephrologists managing patients with severe clinical manifestations of salicylate poisoning should not delay hemodialysis if indicated by physical findings.",
"   </p>",
"   <p>",
"    Salicylates are readily removed by hemodialysis because it has a low-molecular weight and volume of distribution (0.17",
"    <span class=\"nowrap\">",
"     L/kg).",
"    </span>",
"    Although salicylates are highly protein bound at low-plasma levels, at high-plasma levels protein binding falls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/51,58\">",
"     51,58",
"    </a>",
"    ]. Clearances up to 86",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/59\">",
"     59",
"    </a>",
"    ]. Hemodialysis also corrects acid-base and fluid and electrolyte abnormalities, such as metabolic acidosis or hypokalemia typically associated with severe salicylate poisoning. &nbsp;",
"   </p>",
"   <p>",
"    Case reports and case series document that hemodialysis has resulted in survival despite clinical signs of severe salicylate historically associated with death and also shortens the course of salicylate poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/58,60\">",
"     58,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15450524\">",
"    <span class=\"h3\">",
"     Multiple dose activated charcoal",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children and adolescents with signs of salicylate poisoning (eg, tachypnea, anion gap acidosis, altered mental status) or asymptomatic patients who have ingested a large number of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    receive multiple dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC). The initial dose is 1",
"    <span class=\"nowrap\">",
"     gram/kg",
"    </span>",
"    (maximum dose 50 grams) with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    followed by 0.5",
"    <span class=\"nowrap\">",
"     grams/kg",
"    </span>",
"    (maximum dose 50 grams) every four hours",
"    <strong>",
"     without sorbitol",
"    </strong>",
"    until clinical symptoms have resolved and the plasma salicylate concentration is &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Only the first dose of activated charcoal should be given with sorbitol; multiple doses of sorbitol may produce profound dehydration and life-threatening hypernatremia, especially in infants and young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link&amp;anchor=H2#H2\">",
"     \"Enhanced elimination of poisons\", section on 'Multiple-dose activated charcoal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential benefit of MDAC for patients with salicylate poisoning derives primarily from its potential ability to prevent ongoing absorption of retained",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    concretions or enteric coated tablets. &nbsp;",
"   </p>",
"   <p>",
"    MDAC also has been shown to enhance the elimination of salicylates in two small randomized crossover adult volunteer studies and in one observational study of poisoned adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. However, the effect of MDAC in all studies was modest and deemed not clinically significant in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/63\">",
"     63",
"    </a>",
"    ]. Another randomized crossover study of nine poisoned adults found that MDAC did not enhance salicylate clearance when compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MDAC was shown not to decrease salicylate levels after intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    administration in a porcine model [",
"    <a class=\"abstract\" href=\"UTD.htm?18/41/19098/abstract/65\">",
"     65",
"    </a>",
"    ]. Thus, intestinal dialysis does not appear to play a role in its elimination enhancement of salicylates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15449636\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylate-poisoned patients require frequent laboratory monitoring to assess both clinical status and response to therapy. A salicylate level and blood gas should be drawn every two hours until both the plasma salicylate level is falling and the acid-base status is stable or improving for at least two consecutive readings. Patients receiving urinary alkalinization warrant hourly measurements of blood pH, urine pH, and serum potassium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Mental health referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once they are medically stable, patients who have ingested salicylate intentionally should be referred to a mental health professional. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276213587\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview provides key information regarding the diagnosis and treatment of salicylate poisoning in children and adolescents (",
"    <a class=\"graphic graphic_table graphicRef74079 \" href=\"UTD.htm?3/32/3597\">",
"     table 1",
"    </a>",
"    ). Children and adolescents with significant salicylate toxicity should be managed in consultation with a medical toxicologist or advice from a regional Poison Control Center (1-800-222-1222). The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    . In addition, it is advisable to consult with the nephrology service early in a patient's course, even in the absence of indications for acute hemodialysis",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salicylate poisoning in children and adolescents presents with tachypnea, hyperpnea, tinnitus, and unexplained increase in the anion gap and typically follows an acute ingestion. It may also occur as a chronic intoxication or acute on chronic overdose in children who are on",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy (eg, those with Kawasaki disease). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma salicylate concentrations should be measured in all patients in whom salicylate intoxication is suspected, and remeasured every two hours in patients in whom salicylate intoxication is documented. The units of the reported value should be checked carefully since some laboratories report salicylate levels as",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      rather than",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Plasma salicylate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no absolute correlation between the plasma salicylate concentration and symptoms; life-threatening complications of salicylate intoxication may occur when plasma concentrations are decreasing or near-therapeutic. Thus, plasma salicylate concentrations must be interpreted in conjunction with the clinical status of the patient. Nonetheless, plasma salicylate concentrations &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in acute intoxication and &gt;60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in chronic intoxication are indications for hemodialysis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Plasma salicylate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intubation of the salicylate-poisoned patient is dangerous and should be avoided if possible. However, oxygen should be administered as necessary. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous fluids should be administered as needed to replace insensible fluid losses. The fluid should contain dextrose, since salicylate intoxication may decrease central nervous system glucose levels despite a normal peripheral glucose level. Intravenous repletion of renal potassium losses should be provided based upon serum potassium measurements. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Circulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15449105\">",
"       'Supplemental glucose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children and adolescents with an acute salicylate overdose receive gastrointestinal decontamination with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC, 1",
"      <span class=\"nowrap\">",
"       g/kg;",
"      </span>",
"      maximum single dose: 50 grams) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). AC should be withheld in patients who have altered mental status and may not be able to protect their airway, unless endotracheal intubation is performed first. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Gastrointestional decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not performing gastric emptying by gastric lavage or by syrup of ipecac-induced emesis in patients who ingest salicylates (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Gastrointestional decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children and adolescents with salicylate poisoning and clinical findings of toxicity receive urine alkalinization in addition to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      and supportive care (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The goal of this therapy is to achieve a urine pH of &gt;7.5 while maintaining a serum pH no higher than 7.55.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      infusion should continue until the plasma salicylate concentration is &lt;30 to 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (300 to 400",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      2.2 to 2.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and symptoms have resolved. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Urine alkalinization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alkalemia from a respiratory alkalosis is not a contraindication to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      therapy. However, arterial blood gas measurements should be obtained every two hours (along with the plasma salicylate concentration) to prevent severe alkalemia (arterial pH &gt;7.55). In addition, worsening metabolic acidosis or respiratory acidosis despite appropriate therapy are indications for hemodialysis. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Urine alkalinization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children and adolescents with signs of salicylate poisoning (eg, tachypnea, anion gap acidosis, altered mental status) or who have ingested a large number of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      receive multiple dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (MDAC) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Multiple-dose activated charcoal should be continued until the plasma salicylate concentration is &lt;30 to 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (300 to 400",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      2.2 to 2.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and symptoms have resolved. (See",
"      <a class=\"local\" href=\"#H15450524\">",
"       'Multiple dose activated charcoal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend hemodialysis in addition to urine alkalinization and multiple dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      for patients with salicylate poisoning and any one of the following clinical findings (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H33\">",
"       'Hemodialysis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persistent CNS disturbance (eg, coma, seizures) or persistent focal neurologic signs",
"     </li>",
"     <li>",
"      Pulmonary or cerebral edema",
"     </li>",
"     <li>",
"      Renal insufficiency that interferes with salicylate excretion",
"     </li>",
"     <li>",
"      Intractable acidosis",
"     </li>",
"     <li>",
"      Clinical deterioration despite aggressive and appropriate supportive care (eg, worsening metabolic acidosis or the development of respiratory acidosis)",
"     </li>",
"     <li>",
"      Plasma salicylate concentration &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      7.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the setting of acute ingestion or plasma salicylate concentration &gt;60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      4.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the setting of chronic salicylate",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/1\">",
"      Rodgers GB. The effectiveness of child-resistant packaging for aspirin. Arch Pediatr Adolesc Med 2002; 156:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/2\">",
"      Walton WW. An evaluation of the Poison Prevention Packaging Act. Pediatrics 1982; 69:363.",
"     </a>",
"    </li>",
"    <li>",
"     Krenzelok EP, Proudfoot AT. Salicylate toxicity. In: Clinical Management of Poisoning and Drug Overdose, Haddad LM, Winchester J.  (Eds), WB Saunders, Philadelphia 1998. p.675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/4\">",
"      Raschke R, Arnold-Capell PA, Richeson R, Curry SC. Refractory hypoglycemia secondary to topical salicylate intoxication. Arch Intern Med 1991; 151:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/5\">",
"      Bell AJ, Duggin G. Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emerg Med (Fremantle) 2002; 14:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/6\">",
"      O'Donnell KA, Ewald MB. Huffing and puffing to lose weight. Pediatr Emerg Care 2009; 25:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/7\">",
"      Liebelt EL, Shannon MW. Small doses, big problems: a selected review of highly toxic common medications. Pediatr Emerg Care 1993; 9:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/8\">",
"      Botma M, Colquhoun-Flannery W, Leighton S. Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen. Int J Pediatr Otorhinolaryngol 2001; 58:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/9\">",
"      Baxter AJ, Mrvos R, Krenzelok EP. Salicylism and herbal medicine. Am J Emerg Med 2003; 21:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/10\">",
"      Wolowich WR, Hadley CM, Kelley MT, et al. Plasma salicylate from methyl salicylate cream compared to oil of wintergreen. J Toxicol Clin Toxicol 2003; 41:355.",
"     </a>",
"    </li>",
"    <li>",
"     AAPCC annual data reports. www.aapcc.org/dnn/NPDSPoisonData/NPDSAnnualReports.aspx (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/12\">",
"      Clissold SP. Aspirin and related derivatives of salicylic acid. Drugs 1986; 32 Suppl 4:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/13\">",
"      Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 1985; 10:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/14\">",
"      Pierce RP, Gazewood J, Blake RL Jr. Salicylate poisoning from enteric-coated aspirin. Delayed absorption may complicate management. Postgrad Med 1991; 89:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/15\">",
"      Wortzman DJ, Grunfeld A. Delayed absorption following enteric-coated aspirin overdose. Ann Emerg Med 1987; 16:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/16\">",
"      Shkrum MJ, Gay RM, Hudson P. Fatal iatrogenic salicylate intoxication in a long-term user of enteric-coated aspirin. Arch Pathol Lab Med 1989; 113:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/17\">",
"      Orton D, Treharne Jones R, Kaspi T, Richardson R. Plasma salicylate levels after soluble and effervescent aspirin. Br J Clin Pharmacol 1979; 7:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/18\">",
"      Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972; 61:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/19\">",
"      Snodgrass WR. Salicylate toxicity. Pediatr Clin North Am 1986; 33:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/20\">",
"      Chatton JY, Besseghir K, Roch-Ramel F. Salicylic acid permeability properties of the rabbit cortical collecting duct. Am J Physiol 1990; 259:F613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/21\">",
"      Prescott LF, Balali-Mood M, Critchley JA, et al. Diuresis or urinary alkalinisation for salicylate poisoning? Br Med J (Clin Res Ed) 1982; 285:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/22\">",
"      Vree TB, Van Ewijk-Beneken Kolmer EW, Verwey-Van Wissen CP, Hekster YA. Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. Int J Clin Pharmacol Ther 1994; 32:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/23\">",
"      Hill JB. Salicylate intoxication. N Engl J Med 1973; 288:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/24\">",
"      Temple AR. Pathophysiology of aspirin overdosage toxicity, with implications for management. Pediatrics 1978; 62:873.",
"     </a>",
"    </li>",
"    <li>",
"     Flomenbaum N. Salicylates. In: Goldfrank's Toxicologic Emergencies, 9th, Nelson L, Lewin NA, Howland MA, Hoffman RS.  (Eds), McGraw-Hill, New York 2011. p.508.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/26\">",
"      Snodgrass W, Rumack BH, Peterson RG, Holbrook ML. Salicylate toxicity following therapeutic doses in young children. Clin Toxicol 1981; 18:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/27\">",
"      Gaudreault P, Temple AR, Lovejoy FH Jr. The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison. Pediatrics 1982; 70:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/28\">",
"      Cazals Y. Auditory sensori-neural alterations induced by salicylate. Prog Neurobiol 2000; 62:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/29\">",
"      Walters JS, Woodring JH, Stelling CB, Rosenbaum HD. Salicylate-induced pulmonary edema. Radiology 1983; 146:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/30\">",
"      Fisher CJ Jr, Albertson TE, Foulke GE. Salicylate-induced pulmonary edema: clinical characteristics in children. Am J Emerg Med 1985; 3:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/31\">",
"      Dove DJ, Jones T. Delayed coma associated with salicylate intoxication. J Pediatr 1982; 100:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/32\">",
"      WINTERS RW, WHITE JS, HUGHES MC, ORDWAY NK. Disturbances of acid-base equilibrium in salicylate intoxication. Pediatrics 1959; 23:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/33\">",
"      Gabow PA, Anderson RJ, Potts DE, Schrier RW. Acid-base disturbances in the salicylate-intoxicated adult. Arch Intern Med 1978; 138:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/34\">",
"      Eichenholz, A, Mulhausen, RO, Redleaf, PS. Nature of acid-base disturbance in salicylate intoxication. Metabolism 1963; 12:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/35\">",
"      Bartels PD, Lund-Jacobsen H. Blood lactate and ketone body concentrations in salicylate intoxication. Hum Toxicol 1986; 5:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/36\">",
"      Schwartz, R, Landy, G, Taller, D. Organic acid excretion in salicylate intoxication J Pediatr 1965; 66:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/37\">",
"      KAPLAN EH, KENNEDY J, DAVIS J. Effects of salicylate and other benzoates on oxidative enzymes of the tricarboxylic acid cycle in rat tissue homogenates. Arch Biochem Biophys 1954; 51:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/38\">",
"      Miyahara JT, Karler R. Effect of salicylate on oxidative phosphorylation and respiration of mitochondrial fragments. Biochem J 1965; 97:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/39\">",
"      COTTON EK, FAHLBERG VI. HYPOGLYCEMIA WITH SALICYLATE POISONING. A REPORT OF TWO CASES. Am J Dis Child 1964; 108:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/40\">",
"      Giugliano D, Cozzolino D, Ceriello A, et al. Studies on the mechanism of salicylate-induced increase of insulin secretion in man. Diabete Metab 1988; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/41\">",
"      Thurston JH, Pollock PG, Warren SK, Jones EM. Reduced brain glucose with normal plasma glucose in salicylate poisoning. J Clin Invest 1970; 49:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/42\">",
"      Roncaglioni MC, Ulrich MM, Muller AD, et al. The vitamin K-antagonism of salicylate and warfarin. Thromb Res 1986; 42:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/43\">",
"      Park BK, Leck JB. On the mechanism of salicylate-induced hypothrombinaemia. J Pharm Pharmacol 1981; 33:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/44\">",
"      Leatherman JW, Schmitz PG. Fever, hyperdynamic shock, and multiple-system organ failure. A pseudo-sepsis syndrome associated with chronic salicylate intoxication. Chest 1991; 100:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/45\">",
"      Dugandzic, RM, Tierney, MG, Dickinson, GE, et al. Evaluation of the validity of the Done nomogram in the management of acute salicylate intoxication. Ann Emerg Med 1989; 18:11.",
"     </a>",
"    </li>",
"    <li>",
"     Osterhoudt KC, Burns Ewald M, Shannon M, Henretig FM. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.951.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/47\">",
"      Buck ML, Grebe TA, Bond GR. Toxic reaction to salicylate in a newborn infant: similarities to neonatal sepsis. J Pediatr 1993; 122:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/48\">",
"      Chalasani N, Roman J, Jurado RL. Systemic inflammatory response syndrome caused by chronic salicylate intoxication. South Med J 1996; 89:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/49\">",
"      Stolbach AI, Hoffman RS, Nelson LS. Mechanical ventilation was associated with acidemia in a case series of salicylate-poisoned patients. Acad Emerg Med 2008; 15:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/50\">",
"      Greenberg MI, Hendrickson RG, Hofman M. Deleterious effects of endotracheal intubation in salicylate poisoning. Ann Emerg Med 2003; 41:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/51\">",
"      Fertel BS, Nelson LS, Goldfarb DS. The underutilization of hemodialysis in patients with salicylate poisoning. Kidney Int 2009; 75:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/52\">",
"      Dillon EC Jr, Wilton JH, Barlow JC, Watson WA. Large surface area activated charcoal and the inhibition of aspirin absorption. Ann Emerg Med 1989; 18:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/53\">",
"      Decker WJ, Shpall RA, Corby DG, et al. Inhibition of aspirin absorption by activated charcoal and apomorphine. Clin Pharmacol Ther 1969; 10:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/54\">",
"      Levy G, Tsuchiya T. Effect of activated charcoal on aspirin absorption in man. Part I. Clin Pharmacol Ther 1972; 13:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/55\">",
"      Galla JH. Metabolic alkalosis. J Am Soc Nephrol 2000; 11:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/56\">",
"      Morgan AG, Polak A. The excretion of salicylate in salicylate poisoning. Clin Sci 1971; 41:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/57\">",
"      Higgins RM, Connolly JO, Hendry BM. Alkalinization and hemodialysis in severe salicylate poisoning: comparison of elimination techniques in the same patient. Clin Nephrol 1998; 50:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/58\">",
"      THOMSEN AC, DALGARD OZ. Haemodialysis in acute acetylsalicylic acid poisoning. Am J Med 1958; 25:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/59\">",
"      Jacobsen D, Wiik-Larsen E, Bredesen JE. Haemodialysis or haemoperfusion in severe salicylate poisoning? Hum Toxicol 1988; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/60\">",
"      SCHREINER GE, BERMAN LB, GRIFFIN J, FEYS J. Specific therapy for salicylism. N Engl J Med 1955; 253:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/61\">",
"      Hillman RJ, Prescott LF. Treatment of salicylate poisoning with repeated oral charcoal. Br Med J (Clin Res Ed) 1985; 291:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/62\">",
"      Barone JA, Raia JJ, Huang YC. Evaluation of the effects of multiple-dose activated charcoal on the absorption of orally administered salicylate in a simulated toxic ingestion model. Ann Emerg Med 1988; 17:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/63\">",
"      Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Does multiple-dose charcoal therapy enhance salicylate excretion? Arch Intern Med 1990; 150:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/64\">",
"      Mayer AL, Sitar DS, Tenenbein M. Multiple-dose charcoal and whole-bowel irrigation do not increase clearance of absorbed salicylate. Arch Intern Med 1992; 152:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/41/19098/abstract/65\">",
"      Johnson D, Eppler J, Giesbrecht E, et al. Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. Ann Emerg Med 1995; 26:569.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6508 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19098=[""].join("\n");
var outline_f18_41_19098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOKINETICS AND TOXICOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Plasma salicylate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Additional tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15448972\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Airway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15449105\">",
"      - Supplemental glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15449147\">",
"      - Potassium repletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Gastrointestional decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15449335\">",
"      Elimination enhancement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Urine alkalinization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11478562\">",
"      - Treatments to avoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15450524\">",
"      - Multiple dose activated charcoal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15449636\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Mental health referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276213587\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/32/3597\" title=\"table 1\">",
"      Salicylate poisoning in adults - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2970?source=related_link\">",
"      Acute iron poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=related_link\">",
"      Chapter 11B: Regulation of renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=related_link\">",
"      Etiology of hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_41_19099="Survival by LN ratio INT 0089";
var content_f18_41_19099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    5-year survival rates for resected colon cancer according to lymph node ratio in INT-0089",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Endpoint",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Lymph node ratio (total positive/total examined)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;0.05",
"       </td>",
"       <td class=\"subtitle2\">",
"        0.05-0.19",
"       </td>",
"       <td class=\"subtitle2\">",
"        0.2-0.39",
"       </td>",
"       <td class=\"subtitle2\">",
"        0.4-1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall survival, percent",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cause-specific survival, percent",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disease-free survival, percent",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Berger AC et al. J Clin Oncol 2005; 23:8706.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19099=[""].join("\n");
var outline_f18_41_19099=null;
var title_f18_41_19100="Treatments for hiccups";
var content_f18_41_19100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modalities used in the treatment of hiccups",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Physical maneuvers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breath holding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Valsalva maneuver",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breathing into bag",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ice water gargles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Swallowing granulated sugar, hard bread, or peanut butter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drinking from opposite side of glass",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Catheter or cotton swab stimulation of nasooropharynx",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Forceable traction on the tongue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Biting on a lemon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fright",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Noxious odors (inhaling ammonia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pressing on the eyeballs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulling knees to chest or leaning forward to compress the chest",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drug therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipsychotics - chlorpromazine, haloperidol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticonvulsants - phenytoin, valproic acid, carbamazepine, gabapentin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Muscle relaxants - baclofen, cyclobenzaprine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            CNS stimulants - methylphenidate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antiarrhythmic drugs - quinidine sulfate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dopamine antagonists - metoclopramide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricyclic antidepressants - amitriptyline",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19100=[""].join("\n");
var outline_f18_41_19100=null;
var title_f18_41_19101="Lung transplant donor management";
var content_f18_41_19101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cardio-thoracic organ donor management",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Obtain echocardiogram for all potential donors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insert arterial line and two large bore intravenous lines. Consider inserting PAC to monitor patient hemodynamics (placement of PAC is particularly important in patients with an ejection fraction &lt;45 percent or requiring high dose inotropic medication).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolytes",
"        <ul>",
"         <li>",
"          Maintain serum Na &gt;135 and &lt;150 mEq/dL.",
"         </li>",
"         <li>",
"          Maintain serum K &gt;4 and &lt;6 mEq/dL.",
"         </li>",
"         <li>",
"          Assess serum Mg, Ca, PO",
"          <sub>",
"           4",
"          </sub>",
"          and replace as needed.",
"         </li>",
"         <li>",
"          Correct metabolic acidosis with Na bicarbonate and mild hyperventilation. Aim for pH &ge;7.2 and PaCO",
"          <sub>",
"           2",
"          </sub>",
"          30 to 35 mmHg.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventilation: Initial set-up",
"        <ul>",
"         <li>",
"          Mode: Volume control (either assist control or SIMV)",
"         </li>",
"         <li>",
"          Tidal volume: 6 to 12 mL/kg (use ideal body weight)",
"         </li>",
"         <li>",
"          Respiratory rate: 8 to 16 breaths/min",
"         </li>",
"         <li>",
"          PEEP: 5 cm H",
"          <sub>",
"           2",
"          </sub>",
"          O",
"         </li>",
"         <li>",
"          Initial FiO",
"          <sub>",
"           2",
"          </sub>",
"          : 100 percent",
"         </li>",
"        </ul>",
"        Adjustments to initial settings",
"        <ul>",
"         <li>",
"          Adjust rate and tidal volume to maintain mild respiratory alkalosis PaCO",
"          <sub>",
"           2",
"          </sub>",
"          30 to 35 mmHg",
"         </li>",
"         <li>",
"          Adjust tidal volume, pressure profile, and flow rate to keep peak airway pressure &lt;30 cm H",
"          <sub>",
"           2",
"          </sub>",
"          O",
"         </li>",
"         <li>",
"          Titrate FiO",
"          <sub>",
"           2",
"          </sub>",
"          to maintain pulse oxygen saturation &gt;95 percent or PaO",
"          <sub>",
"           2",
"          </sub>",
"          &gt;90 mmHg",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hormonal resuscitation",
"        <ul>",
"         <li>",
"          Tri-iodothyronine (T3): 4 mcg bolus intravenously; 3 mcg/hour continuous infusion.",
"         </li>",
"         <li>",
"          Arginine vasopressin: 1 unit bolus intravenously, 0.5 to 4.0 unit/hour continuous infusion, if hypotension or urinary output &gt;1000 mL/hour. Titrate to maintain SVR to 800 to 1200 dyne/sec/cm",
"          <sup>",
"           5",
"          </sup>",
"          and urinary output 100 to 200 mL/hour.",
"         </li>",
"         <li>",
"          Methylprednisolone 15 mg/kg intravenous infusion; repeat every 24 hours.",
"         </li>",
"         <li>",
"          Insulin: To achieve a target blood glucose range (120 to 180 mg/dL), avoid the use of glucose-containing intravenous fluids and administer insulin only when necessary. There is no universally accepted insulin regimen.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume resuscitation: Maintain a mean arterial pressure &gt;60 mmHg, systolic blood pressure &gt;90 mmHg a PCWP of 8 to 12 mmHg or CVP 6 to 8 mmHg, using colloid in preference to crystalloid",
"        <ul>",
"         <li>",
"          Infuse albumin if INR and PTT are normal",
"         </li>",
"         <li>",
"          Infuse fresh frozen plasma if INR or PTT are abnormal (eg, &ge;1.5 x control)",
"         </li>",
"         <li>",
"          Infuse packed RBC to maintain blood hemoglobin &ge;10 mg/dL or hematocrit &ge;30",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressors: Aim for systolic blood pressure &gt;90 mmHg",
"        <ul>",
"         <li>",
"          See arginine vasopressin above",
"         </li>",
"         <li>",
"          Norepinephrine",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repeat echocardiogram when patient has stabilized. An unstable donor has not met two or more of the following criteria:",
"        <ul>",
"         <li>",
"          Mean arterial pressure &ge;60 mmHg",
"         </li>",
"         <li>",
"          CVP &le;12 mm Hg",
"         </li>",
"         <li>",
"          PCWP &le;12 mm Hg",
"         </li>",
"         <li>",
"          SVR 800 to 1200 dynes/sec/cm",
"          <sup>",
"           5",
"          </sup>",
"         </li>",
"         <li>",
"          Left ventricular stroke work index &gt;15",
"         </li>",
"         <li>",
"          Dopamine dosage &lt;10 mcg/kg/min",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PAC: pulmonary artery catheter; Na: sodium; K: potassium; Mg: magnesium; Ca: calcium; PaCO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial tension of carbon dioxide; SIMV: synchronized intermittent mandatory ventilation; PEEP: positive end expiratory pressure; FiO",
"     <sub>",
"      2",
"     </sub>",
"     : inspired oxygen concentration; PaO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial tension of oxygen; SVR: systemic vascular resistance; PCWP: pulmonary capillary wedge pressure; CVP: central venous pressure; INR: international normalized ratio; PTT: partial thromboplastin time; RBC: red blood cells.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Critical Pathway for the Organ Donor. UNOS, 2006. Available at: file://www.unos.org/docs/Critical_Pathway.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19101=[""].join("\n");
var outline_f18_41_19101=null;
var title_f18_41_19102="Tzanck preparation";
var content_f18_41_19102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tzanck preparation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD19wSakiGKVRmn7a+XSPQEJ4pMUEUdKYDlUU/bUYbFHmetIBxGabinBgaWgCPHHNRSL6VOfaozjNOwEQXFBFPIphbBpWHcFyDzT88UzI60Z5pWAkVuKeDkVCmM5p24CqSExxNNZqXINMkYAVSQiKdhjNYerXOyF/pWpcyAIea47XrojcM5HNdeHhdkyOG8WSNLG7jvXm14jjcQK9D1x8xkt0rgNQkCseeK+goq0bHMzCfcWORUbIT0p87ksSKh3tjrWjJFC808ttFRK+OvWiQ5FK5VhC5B4qVQTGSe9QKBmpvNA4qgKdxlVOKhidu9XJsEZqmxAPFJLW4myYyELU9nerCpz1qoeVqD2FUTJtbG1a3XnNzwa24pQYlANcxYxN1wcV0NmvyjNTIcfM0YlwAQauKq+VvdulU9+1QqinXoK2DPk0mWinqF4XcAH5RVSG7CyDnmqkrk9KhjVi+TVIV2ev8AgjxCVVIZyMHoa9U027DquCMGvmbTLt4pVAYjB9a9e8H6u8qRI7c8d68/GYZNcyNIyPVonG0elTRgbs1l2UuVAJrQRq8KcbM3RaODUctvDMpSWKORD1VlBBpVNPWsHFFJtHG3Hwv8GzzvLJoluHc5O0so/IHiiu0xRReXdl+1n3JkXFOY8UZBpGqjIaTUbNT+DTHTjjrSGMaTAqJpwe9JOh28VkTyNG/NJopGwtxg8mrcThxwawYZfMHBq9byFWHNKL7ja7GpjFQt1oEoIpCe9WQFNdM049KTdxTAYVK0jnI4qTIpjYGPeiwXGxLsHXJoZjnFK8ioKYSG5HSmkFx24gVHK3y0uaryycEVcUBQ1Gbah5rh9auDls10Ws3G0HmuI1KYs53HivUwsDGbMfUm+0IQelcTq9sImbPI7V2dx82QOlc9e2xkZo5O/SvVpuxgcZMAScVXIrcurD7NuLA+1UHjBU8Vo0K5URB3pkh5wKew2nAqPBLdOKmxXMM3YqNnI5FWGGB0pkKq7YaqQmyv5hcYIprVp3EESINhGaoPlm2gU7EsgZsUsMe5qsC2IxuqxHaNjKmkJLuX7YosYGK0rQAsPSseJJUIDrWnBuTaQRigZqKRuxiq+rORbFQflParMTDZkYJNQ3cZ+yuZOlK5aOaaba4XaTnvVhWyvAqByMnbU1urHBI4poRZghdiCAa7Xw/dyWypg8qRXP2d5FHbmNlG49K1LSTy4PMH1qZK6sWj2bw7qYubdCTzXVwMrqN1eM+FNXZGUNwDXqem3Sugww5rw8XQ5WbRZvK4PAqRaqQnODVgNg15slY1J+aKi8z6UVmBaXIp+MjmkJAoBqiQCc08pkUqso6mnqy9RyKdguU5Ux1rNu7USA461uyqGGRVFkIc5pDTMCKFonxzWjF0HrVl4AxpPK29KdrjuIp5qwDkVEEqQLjpRYVwwc07bxVeSWdWJEeVFSwzpMuBw3cUwEwaMZp54NNNAXIpIPMbIYgd6cUCKFXoKUt2pGPFUl1AhY4NVbgjaT0q268VkalLsVueK1pq7Jbsct4iuUj3lmA4rznWNWBkYRnp71q+Kr/z7yRd+FHFcJeyjzSFOea+gw9JRjqc7dzQGtsnyuuR65qeG6jvBuXG4VzLsC1T6fN5VwpU8V02XQzZsXSLIpWQDFc1f7ISUTn3rf1GUsBg9awroK3DdapIgyTgk0AhW6VcNsBzmhLdc8jNKw7FaYqV6VVRWZ/lHNassI2HjiqBmWM4XiqDYnFk7JudsVCY0jbsTSm6LDGSajcnikwV2SScgc1NbyKi4PWqqgk1J5ZAzSHYmmuG20xbh8AEnFNB3Ag0sMYZj6UXEkXLO6eJgQSR6VueeLy3wBweCK57Hl89qv6TcbJsZ4ak0UnYc+jyiQMqkqT6VLc6dJFECAa6K3nzF2NQyy7gQw4qdS7nHLFMZs8jFdNbSlbdFbpiql+fmCqOtTQkrAA+KavYatcux6isJAU7ce9ej+CtXa5jCs2ce9ePXbRNKOeRXWeBr4wXqhT8prCvSc4O479j3yzfcgOauK2awdKug8a89RW1EQcGvnqkLM3i7lmiiisLFXLppwFIpzQcipAjkikLExtwafChjTaSSaepNOPNAr9ABwKGUNQOnNA4NMQ0oPSonTBqcnFMYZoAh296UAU402mMevFRPAhl3qMN7Ub8GnB880AMZTmmnipGcVETk0AMbrSPnbxUhApSQVIHWqQNlV3H3c81zXiafybaVh2Fb08bBgFXBzya5Lx1L5emyEda7MNG80RPY8R1q6klvXO44JrGncg1cvX3TMfes+QZ5NfRehgI5O3NNtJCJqY7ELio4mw2RTIkbFxdfu81lMxZ8mp2BcD0pCoA5FUyUrEW4kj0FPWVeg60wjOcVCPvUrjLwO6BvYVzkobzTn1rYkmMaEA9az3UM2aGJIiVSB3qdORzUbNngVJGMLzSKHLgGpc5FNXB69akwMUCtcYqknAqeNdtNhRncAVZki2DrzRYRDKCy4NWdLgG/LN0qtI4VCO9RwykNlTigo6y0VlfGeKtOmVNYulX+X2S5z2NaN1dEKAvSpd7jRXuUx8x7U5wr2u4HBFQ3JZ061SmmZV2g8VSRRCy7pK6Pw2yRSht2GBrkvtwjc8ZNTWWosLgMDim1dWFc+ifDlyJIUZTkYFdfZNuArynwHqW+JFY+lenadIGA9K8DF0+WTNoM1w1FAxiivPNS8opxIpo4FJ1NZWAkFIetNOaACetFgJAc0EHrTBxUgPFAhKOlITTS1MBH9qh5qUdeaaRmgZWk4piMe9TyLULcCqQCk80oIzVV5dpoSQls0irF4KCKjKEHinxOCKVuRxVokrTHjFcV44i8zTpQO1dpN0Ncl4kQzW8iE9RXXhnaaM5bHguoQCNyax585OK6LW4WW4ZMdDWJKgGQetfRIxKAyfvVEBh6sSrtBqCM5fFPYhlyIFl4psuRxTlJQUoG881QiHGFqvIverEoIb2pAu480bgUpVJFQlcVduRt6VTc7qm1gREfvVJu7U1eG5pWBJ4FAyVT3p4kBHNQBihwT1qVUyODSAUTMjZWneY0jbiTUeMNhqd5gj6UXCwTknGaRcBcjrUUku85NNWQ9BQM2dPZNuW6itNpQUGK5mK4IO3pmtazlzGF6mmC3GyytvJLYFUZ7jrg1ZvIJCrHBFYk5ZSQc0rjegkkm5jU9lIPNXJ71nMSDxVmzUtIKXMQr3PWfCN4kckO1hg4Br2PSJv3SnPavnTw/M0E8bHOAQcV7N4f1PfGmTwRXm45X1R001qegrPwORRWMt18oorxuY6OQ7fANJwKA3rS4zWRAhPFND06mlQTQIZI3PFPjYmgR1IFxSGJQBTiOKSnYQhWm8A4qQdKjfrTAim4HFUpXxx3qxdShEOa5+71BVY88VrCm5bBctTctxViJflFYUerRO2AwzWnbXKuBhgRVyotbj5jQRsGp93FVo2UjrTzIucZqOURFcSYBzXO6woeNjW/cAMDWFfrwwPSt6OjFLY8l8W2RSUzRjjvXItCHfNeo61Gjh1IyK891SFreVmUcZr36Erxscz3MDUU8s4xVOIbfmNaNzm4fnrUZs5CvA4rcgYJFdeetA45FIIJIzkqcVKig0wsQMdxoONvHWpvKLMRg8UfZ27jihDaKF1krmqqKCCTWtNBlDWbLGyHpUsCHZ81TeWAM0JjvTJpgOBSQrkMoy2adHLtXBpqkPUb4GRmgocZsmmF+aj2HrTsYGaQCc5pyHsaI2z1qUIGpgOjj7k1YhuGgkB7VVfKL1pocuBntQmO1jdmuS8O5ulUWtRc8oKU5ktMLV/SVMceD1NJauyBuyuY02mSKMhafaWrRfM4ropD83PSp7Dyri5WNsVTiwulqM0EK0gMg4zxXqWjxbbaMqO1ctBpUR2sq4x6V6H4bswbSJSO1efi/huaU5GhER5a5BziitZbMbRgUV43Kjo5zrCMUqnmpQA1NZMGuYm41qQDmnCl4oAUUtFGRimAhOBTd1Nc0wtQCJc1HK2FJ9KRW4qrfzeXExoirsGc94j1MQjAPJ968+1fxCyFkX+dO8c+IY4bho1OWGRXAT6j5xL+tfQYbDcsU2jGUrnRLrjKwOTn61tWHigpt+b9a82a8zxipIrnAzmuqVGLWqI5j2uw8TxyqAzYb61tW+pJMAVcfnXgdvqjI3ysa2bPxHNCRhjXLUwSexoqh7b9pyOtZ9828HBrh7DxerKBICTW5FqQvI90Z4rl+ryg9Sua5laknEhJ6VyOpoJo2G2uu1LMiOBXOXUQVXJ7A16FHQ55HB3MZhuCM9KVZnA5PFGoEy3j46ZqK7haJR712PTUS1JTKSpHWoY/wDWZqJGZAMjNTqhPIFJO5Vhxkw/FWAzSLgCqki7etTW8gxiqEy0lpuTLN+FLJYR+UTJigFtuQar3VwxG1jxRa5N2ZV5borERHNUHtj3rXIAUs1UWbJOaTQIoMhXgVEyEHJPNX2AJqCZAcFuoqWMgAOOaUxEjOaHPegNxwaChREFXPehHwTUZkxwaTI7UBdEsz7k6VV87bwKlO9hhFPNSW+lTS/MVpImTb2NHRmDxNvHfirwcK+1eKSztTbxBdvNVrxJVkDgEVaAuzyhB8x5plm+JQ6HDA1R80uPnHNXNOTdKDjAFO7Ha51mk6ncSTRxOMrkCvXvDbq1shHYV5Bo0am4GO1ep+GWHlBQegrz8Z8OhrBI7VHXaKKqLjaKK8axodUBtNDPzjvSk5NIQDXIWA5owQaaGwakzxQAydXe3kWNtrlSA3oapaXDNaWixXEzTSZJLGrbPg4pgGTQg8hSSTmlxxTwBikIoAbtrI17ItZMelbFZurLvhIIyK0pu0kJnzH4umb+1Z9+eGNYKze/Fd38QNJCapK4GAxJrz26jaKbHUV9TCd4po55Iv43R7lIpEkwCDVeIts4puecmtE7iaJZHKciiO9kX3qMsHWmqmDntSCxrWmolWG9eK6vRtYjhdSsg2ngiuHMi7MYpsE5jkBzxScFJWBOx7PIyywh0OQRkGse8hEgZfWneHrr7RpyHOccVZuEwSRXPFcrsKRwOq20VuWzw+aw3n8whT0FdF4kK+c+7rmuaVFZ+DXVfQaLSLlc+lSxSKcqeDVJnIBANEZz160xssXJ3jjmoIceYAelPwRz1oCAndTJaNaPy3iCqeayb5GW45HFX7Zfk3U6WITRnPUdKEQzJu2V4lVOKotC2M1fuIimcDkVUabCkEUMEUmGw9ahlbd1NTyfMc1UuFOM5qWUmNkYBOtVhPg8VHK+OKZGu5qyctROTexZUNM3yjrWpZ2AYjfTbGIBAcVpLKsXQZrWOpL0LMVnGoHarIUJjZWb9sYtUqXmOtOyFdmvFgtlsCpJRC6FMA1lrdBhkHBpy3i9xz607DTI7qx2NvQZFPgdFwMgGphOGHJ4rPuY/wB7uQ8UFpnUaO4EoxXofhORjIc9K818PMSMOPoa9N8LqAoIrixXws1gztE+6OaKRPuCivFsbnVq2amQZFRLGQKkQ9q4wBlA5pO1Oc01TSAjKnPSlHAqVhkVE4OOKaAFOTUgORUKZzUwGBQwEaq1zHvQipmbmmO3y007AeW/EHTBPbuwX5lBNeI3sRWZ1Ycg19NeI7UTQOMZyDXgPiay8jVZUxjmvewNbmjysynHW5ziuFXaKjlORxU9xEUbGKr4JOK9FGbIUU7s1bLKFAJ5pEiGPm61XmUg0lZICxsPbpUTjBqxp8gYFH/Corxdsh9KpMR2vgS6LQtFnkHpXZSKJFGOvcV5X4TvDbanHzhWODXrUC5iL9ciuaro7ha5574viCyOV7da5GMEvXp3inTRLZGVBlj1xXnr2pQnb1raDugRA6EHPanRDPJqXDdGFSwwZHPFWOxESQOlOhZTndUrIqkBjxUU6qoytMCdbpVQqtNS4K5yeDWdvweKN7M4FBDRsgRzR+9Y+oW20/LV98w26t0zUJYSLljTuKxmiMKmGFZd4CrcdDW1dSBhtHase8+Y4xSmCMuUc5qxYxlm6UJCZHArWtrcRJ05rn5XcFpqMDtGNtSKHfkVG4LPzVgvtTAraOiB6lVi0bfMadGSxzniobhtx5NRByBgGquKxYnlI4DcUsd2eBnNUny3AqVIwE680XA0I7py2Bg1b3nbyKyLUlG3E9K1bRxcAgdaLjOi0WTdsVevFeoeE9wiANeZaBCIpFA5Y16x4bixEhA7VxYt2iaw3OqQfIKKkRTsFFeLc6LHWqc0hABo6UZBrjAY4zTY1OamABp1ABik2iloNAiCT5RwKYsjBsE5FTMwB5qJ0B+7xQ2UhTzUEwOOKkJxTXOVoAzL2PzImFeN/EjS3jl+0xr9a9qdTkiub8TaYLqB1Zcg134OrySJkrnzjPOZflI5FVgD+NdH4k8Pz2N0zRoTHXOSrIueCDX0EZJq6Od6EZaTPWmrl2ANAkKt8wp4ZGbOcGjcVxfKKNkHmnSEuPm60yYkYIOaI5C3HeqXYVx1kWiuUb0Ne8+G0W60iA7clkGc14lZQl50BHJNfQvhSyMOl2ykY+Qfyrjxk+WKNYIyb7TNkTIRlTXm2t2As7okAbTzXuV7aFlPFcL4s0Q3ELMi/MBWOFxF3ZhKNjyi6bMpIFLEcirdxbtbysjpyDVKRgr4AxmvTTJIpHDPioLmXC7BU0y7FLY5qnBBJcSbVGSaYmNQruGTWpFbxlAyAE1FNpTRRb92TSWUojJVjQQ9RNSl2xqhpsCCS3LDqKhvpFmuPk6CrMcqpBsA5oQkZFxkOfrUDorAZ61cuYWZiVBqiY2zzQwJLaFRKCBmth7dRbE45xWXbHY4zW6Dvg9iKWgmYD/KTUTsSDin3p8iUgjiqfmbjkUihXxg561Cx9KlYEnmmKvPSi4WFjGcVM4ATHekjUijcHJA5xTCxXbdjANbnh7HzbutZBjO7Na+mROE3KO9FxWOs0jd9pXaO4r1/wAOR7bdB3xXl3hiLzJIxjnIJr1rSIzGi/SvOx0+hvTRuA8UUqjgUV490bHR5NKnWmZpVOK5Rk9AOai3GlDGgViUnFM3ZpQRimUAQysRTkPFMnGVqAOyMAKZVrllhUbVJ1GahkzQIZwTUF2gdcEZqQZJpCPWri7MLHA+J9LV1b5R+VebappiIzEoPyr3LVrTzQeOMVwGvaXG24Hg817GFr30ZnKN0eTXdpGXOFqjJZlT8prqtQsljlZe4rJlhJJ2ivUVmc7RiFGXg9KmtQofkVpCzaRSNvNS6XoN3e3YihiJJ9qG0tQjdnQ+AdCOq6qksg/cRnJ46171Y2ojiUAYAGBXP+CPDg0fT0RgPMbljXYKm3HFeFjK/tJ6bI6IqyIXiBGCKwtWswyNtHaulYZFUriMMCDXNTm4u42rnkXiPRBKWdFw30rhL6xkgkLMnT2r3fVtO3gkCuH1rRy6P8te1QxF1ZmTVjy+4nD4BUADinWcqQyAgZFXtS0uSF2yvGaxZYpIyStdqaZDNe9vYfIODye1czLL85IPWp2LvncKpvjeaeyJtYkhJDZNX7Rd+WYfKKzUbmra3PlQlR3pp6AaSurngcVWvbdG+ZOvfFVre47etW0dRy3SnoxGbLE0fOOKv6VcK7eUx57VLtjdWyeMVQjjEc29OxpAW9Z0/wA2EsgyRXNxxMJAuDmu0tJvPTB+93qvdaciv5iLzUjOekiPHHNCQHqa0bqIr8xXAquTmIkUDRVJwcAU+ztsM79jT0jBTJHNW4Y2ZdqDrTGRQwiecRouSfSumhsRDCqYqLRtPSDMr434rotGtDf3KoBlc81E52HGNzf8E6b8okK+mOK9Hsrbao9ao+H9MWCJQB0Aroo4dorwcTX55NnRFWGiMY6UVOEorhuWaQpaMUZOazEHeikOTSZwaaACSKdnikA3UuMCgCMjmkIyRxSvSpyKFoAoGVpGXinZxS4yKdxFNvv4qTYMZp5j+bNP209gKcsYZSDXLeIdEa5QtEcNzXZFKgnjBU8VrSquDugPILnwxO7ZdcsPeo4vBk8p4Qg16otkDJkitGC1VB90V2vHyS0JcUeXWXgJ1cNJ07iu00XQobFAEQBvpXTiJdvSq5Ta3FYVMXOpo2CikEceynscClAwOaUjNc9xld3x1qMJvNPnSiLAGKoCGa33jpWPfaarhuK6dQCKrSwbmNVCo4sGrnmGt6EJVbC81wWr6Y9qxBjr32609ZAcisDU9EikUh4lP4V6NDGJbmbifOOoMyuV24rMYHOTXqfivwgxZpLdD9AK89u9PmgdldGyPavUjUjNaGbi0ZyruPFLNEMDBqdIjuwQQabcxlCK0RNiKFcEVfUK6YNVIV3VeWIhBimrWFYrsGVsA8VatERwQeDVdsBsbgT6VYi2svHDChgRtJJZ3AZelbdrexXMeWwCazJ1DxYcZam2tu4PGQKl6jtc0ry1M8RWIg5rH/s2ZX2kDH1rVaVo0wp5qus0rkljzQh2sLa6WjECRsD2q+EtrUYQAkVnwpO8uCWwa6bR9FScjziTntUzkoq7ZSjcx7FLi/vAkSnGe1eseF9F+zRKdvPrUnh3QLe1RWjiXPriuwtIBGoGK8rFYrm92JtGNiWxi2IBV7timxL7U/FeRJ3NBMUU7FFQMvE4pNwobFNzQSSDBo25pi1MlADQMUjU9uhFMRNqYyWPqaBDGGRTBlalPBpMZNIYzOacDgYpwTFLsB70AICO9B9qR0Paom3CncVh7kgZxmmkE9qeo3AZqQLTuBEiAdqkFIRg0oNO4DweKYRznFBpQeKEIjfpTSaV6YBzTGRy801FJqSUgUsA5yaq+giVQQKTBqYAUYqLjIGXPWq8kAbPFXWFMK8UKVgMW602ORTlAa47WPB9vLM0qxDJ6ivSGXNQyQhu1b08ROGwWR4Dr/g14pTLBHhfSuSv9KmD7TGfyr6eurGN1OVB/Cud1Dw/byZZUGfTFelRzDpIhwTPno6XJCNzLxUE0hB2gcCvbL/w/GylfL/SufufBwkyUUD8K7Y4uD3M3A8qWNN+cHNWYiAcgZrsLzwVciTEY4+lS2Hg6WFWM4JP0rRVqcVoJxbepx8RZ3yVyBUsrzFgsa9fau2j8NbemB+FaVn4ejVwWQH8Kl4iCHynn0VjduMhCc1qadoE0hDSLXptvpURUKEH5VoQaWEwAv6VzzxtloVGNzg7Lw8Ay5XFdpo+gRRqpYc1u22nocEqM/StKO3CAYrgq4py0NEiO0tljQKo4FW1j5qSJMCpVXJrilK5Q5VASkNSqvHNBXFYtjGBeKKdiipuMlYU08Gl3UwnmmSSKalU4FQoRmpVxTQMU80mMUpIFNZvkOBzRcQnWlXg0qkbBnrSgigBTSUpIIpm/FIBWYimdTUTbmlyT8o7VItAyQcU7oaBS4zTEIeaiIxUp4pjcihACn1pSKQUqjJpgNK0m2pTSHmi4EBi3HmpVQCnAU7FFwEApaXFIakBpNNJpSc0mOKYDe9IRT8U3FUBDIvFUHTLGtRqqSrhqpMChLaqeoFRizXsK0iu6neV8tV7RoLGFLYqW+7TX05Sh+WtwxDOaide1P2rCyOa/spRJkCriaeoT7tbKxA9RTzgDGKftn1G4mDFb7HwRWlFCNnvUjxbmzipEQg0pVLqw7CRx4NWAlKqU9VIrLmATb2qRBg0qgU/AqXIBe1JTscUlS2A3FFLRSuAEUw8U4nim9TQAi9amQ00AUdDxTAeaAOaZv5p60XEOamMDTiDTc02Ih8whsGnE5GaV0BGaavTFSygUZqZFqNBg1MlAmLyD7U8HNJ1pucUxA5FA5GKjLc05WouMeV+Wqrs6nKmrgORTTGpHNVd20EnZ6jUbevIpwpFAHC06kAEUhOKCe9JuoAdmlzUec0M6qOTQFhWHekzmk3bvpUUkmDii9tQ8iY0yhXyoNLxVANY1GyBqkZfSgDii4EYQLRzUhHFM71DZQxhmozHzmp80h5ouBEF9qa0RJ6VYUAU4kAU+YCFFVetNYZbgcUrnLU9RxRcBgBFTKMijFOUYpXATbxSAU8ikIpXGITQrc0UEAc0mwF4oqPevrRU8wWZ/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This Tzank preparation of a specimen from a patient with herpes simplex virus infection demonstrates a multinucleated giant cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19102=[""].join("\n");
var outline_f18_41_19102=null;
var title_f18_41_19103="Dysostosis lumbar vertebrae";
var content_f18_41_19103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dysostosis lumbar vertebrae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dysostosis multiplex, with hypoplasia of the anterosuperior areas of the lower thoracic and upper lumbar vertebral bodies, resulting in prominent beaking of one of the lumbar vertebral bodies (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_41_19103=[""].join("\n");
var outline_f18_41_19103=null;
